content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="margin: 0"></P>
  
  <HR SIZE="4" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">
  
  <HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-Q</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
      <TD COLSPAN="2" STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark One)</FONT></TD></TR>
  <TR>
      <TD STYLE="width: 6%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 94%; line-height: 115%">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9746;</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
  <TR>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR>
      <TD COLSPAN="2" STYLE="text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the quarterly period ended December 31, 2017</B></FONT></TD></TR>
  <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the transition period from ______to______</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <B>000-54163</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR>
      <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NuLife Sciences, Inc.</B></FONT></TD></TR>
  <TR>
      <TD STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact name of registrant as specified in&nbsp;its Charter)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
      <TD STYLE="width: 5%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 46%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46-3876675</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction of</P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">incorporation or organization)</P></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employee Identification No.)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2618 San Miguel, Suite 203</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Newport Beach, CA</B></P></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>92660</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive office)</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(949) 973-0684</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number,
  including area code)</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Not Applicable</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B>(Former Name, former address
  and former fiscal year, if changed since last report)</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
  by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
  Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and
  (2) has been subject to such filing requirements for the past 90 days.</FONT><BR>
  <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes&nbsp;</FONT> <FONT STYLE="font: 10pt MS Mincho">&#9746;</FONT>
  <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;No&nbsp;</FONT> <FONT STYLE="font-family: MS Mincho; font-size: 10pt">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
  by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
  Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
  preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;</FONT>
  <FONT STYLE="font: 10pt MS Mincho">&#9746;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;No&nbsp;</FONT>
  <FONT STYLE="font-family: MS Mincho; font-size: 10pt">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
  of &ldquo;large accelerated filer,&rdquo;&nbsp;&ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule
  12b-2 of the Exchange Act:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 43%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
      <TD STYLE="width: 18%; line-height: 115%"><FONT STYLE="font-family: MS Mincho; font-size: 10pt">&#9744;</FONT></TD>
      <TD STYLE="width: 23%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
      <TD STYLE="width: 16%; line-height: 115%"><FONT STYLE="font-family: MS Mincho; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer (Do not check if smaller reporting company)</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: MS Mincho; font-size: 10pt">&#9744;</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt MS Mincho">&#9746;</FONT></TD></TR>
  </TABLE>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
  by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp; Yes&nbsp;</FONT><FONT STYLE="font-family: MS Mincho">&#9744;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;No
  &#9746;</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate the number of shares outstanding
  of each of the issuer&rsquo;s classes of common stock as of the latest practicable date: As of February 20, 2017, there were 40,504,391
  shares of $0.001 par value common stock, issued and outstanding.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  
  
  
  <HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">
  
  <HR SIZE="4" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="TableOfContents"></A>PART I: <A HREF="#a_001">FINANCIAL INFORMATION</A></B></FONT></TD>
      <TD STYLE="width: 5%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1: <A HREF="#a_002">Financial Statements</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2: <A HREF="#a_003">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operation</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3: <A HREF="#a_004">Quantitative and Qualitative Disclosures about Market Risk</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4: <A HREF="#a_005">Controls and Procedures</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART II: <A HREF="#a_006">OTHER INFORMATION</A></B></FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1: <A HREF="#a_007">Legal Proceedings</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A: <A HREF="#a_008">Risk Factors</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2: <A HREF="#a_009">Unregistered Sales of Equity Securities and Use of Proceeds</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3: <A HREF="#a_010">Defaults Upon Senior Securities</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">28</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4: <A HREF="#a_011">Mine Safety Disclosures</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">28</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5: <A HREF="#a_012">Other Information</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6: <A HREF="#a_013">Exhibits</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_014">SIGNATURES</A></B></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">29</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 8pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><A NAME="a_001"></A>PART I - FINANCIAL INFORMATION</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0"><A NAME="a_002"></A><B>ITEM 1.&nbsp; FINANCIAL STATEMENTS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>NuLife Sciences, Inc.
  (fka &ldquo;SmooFi, Inc.&rdquo;)</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>Condensed Consolidated
  Balance Sheets</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>December 31, </B></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2017</B></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2017</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">ASSETS</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="width: 63%; font: 10pt Times New Roman, Times, Serif; text-indent: 22.5pt">Cash</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">40</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">44,123</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">Prepaid expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 22.5pt">Advances receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,090</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.5in; padding-left: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">50,213</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Security deposit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,871</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,871</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,911</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">55,084</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; DEFICIT</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">Accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">610,410</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">633,689</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">Due to related parties</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">135,730</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">84,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">Accrued interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">35,821</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36,508</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">Notes payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">205,910</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">99,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 22.5pt">Convertible note, current portion, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">92,380</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">58,432</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">TOTAL CURRENT LIABILITIES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,080,251</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">912,629</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 22.5pt">Convertible notes, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,177</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 22.5pt">Derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">102,559</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">231,733</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">TOTAL LONG TERM LIABILITIES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">116,736</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">254,760</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">TOTAL LIABILITIES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,196,987</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,167,389</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">STOCKHOLDERS&rsquo; DEFICIT:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 22.5pt">Preferred stock Series A, $0.001 par value; 15,000,000 shares authorized; 117,500 and 117,500 issued or outstanding, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">118</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">118</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 22.5pt">Preferred stock Series B, $0.001 par value; 10,000,000 shares authorized; nil and 10,000,000 issued or outstanding, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 22.5pt">Common stock, $0.001 par value; 475,000,000 shares authorized; 40,504,391 and 37,797,238 shares issued and outstanding, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,504</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37,797</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">Additional paid in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,251,065</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,445,385</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 22.5pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,483,763</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,605,605</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">TOTAL STOCKHOLDERS&rsquo; DEFICIT</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,192,076</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,112,305</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; DEFICIT</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,911</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">55,084</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">The accompanying notes are
  an integral part of these financial statements.</P>
  
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>NuLife Sciences, Inc.
  (fka &ldquo;SmooFi, Inc.&rdquo;)</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>Condensed Consolidated
  Statements of Operations</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>For the Three Months Ended
  December 31, 2017 and 2016</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>(Unaudited)</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Cost of sales</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Gross Profit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expense:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 63%; font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative expenses</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(768,775</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 8%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(98,856</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Related party compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(42,994</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(303,404</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total operating expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(811,769</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(402,260</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(811,769</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(402,260</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(201,254</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(36,479</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">504</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Forgiveness of accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73,644</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Gain (loss) on change in fair value of derivative and derivative expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">61,221</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14,319</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss before provision for income tax</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(878,158</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(452,554</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Provision for income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(878,158</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(452,554</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &ndash; basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">38,209,901</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">31,085,800</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">The accompanying notes are
  an integral part of these financial statements.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 5 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>NuLife Sciences, Inc.
  (fka &ldquo;SmooFi, Inc.&rdquo;)</B></P>
  
  <P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Condensed Consolidated Statement of
  Cash Flows</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>For the Three Months Ended
  December 31, 2017 and 2016</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>(Unaudited)</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOW FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="width: 63%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">(878,158</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">(452,554</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense - amortization of debt discount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">170,765</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27,495</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">(Gain) loss on change in fair value of derivative and derivative expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(61,221</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,319</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">640,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">186,904</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Forgiveness of accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(73,644</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Note receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(504</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable and accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,365</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">35,656</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Due to related party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">52,320</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,867</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accrued interest payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,080</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,983</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Cash Used in Operating Activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(92,493</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(182,568</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOW FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loan proceeds</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">106,410</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">685,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds from the issuance of convertible notes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Payment of convertible notes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(78,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Cash Provided by Financing Activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">48,410</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">685,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">CHANGE IN CASH</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(44,083</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">502,432</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">CASH AT BEGINNING OF PERIOD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44,123</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,086</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">CASH AT END OF PERIOD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">40</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">503,518</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid for:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">NON-CASH INVESTING AND FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Shares issued for convertible debt and interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">77,767</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Derivative liability written off due to payment of debt</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">67,953</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Initial value of beneficial conversion feature</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">The accompanying notes are
  an integral part of these financial statements.</P>
  
  
  <!-- Field: Page; Sequence: 6 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NULIFE SCIENCES, INC. AND SUBSIDIARIES</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
  STATEMENTS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DECEMBER 31, 2017 and 2016</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - ORGANIZATION</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">NuLife Sciences
  Inc., formerly SmooFi, Inc. (the &quot;Company&quot;) was incorporated under the laws of the State of Nevada on October 15, 2013.
  The Company issued 7,250,000 shares of its common stock to our founder, Derek Cahill, as consideration for the purchase of a business
  plan along with a website.&nbsp;<FONT STYLE="background-color: white">On April 21, 2015, the Board of Directors of the Company
  approved a three-for-one forward stock split of the Company's common stock (the &ldquo;Forward Split&rdquo;). Accordingly, shareholders
  owning shares of the Company's common stock received two additional shares of the Company for each share they owned, and Mr. Cahill&rsquo;s
  7,250,000 shares became 21,750,000 shares. Prior to the Forward Split the Company had 10,128,600 shares issued and outstanding
  and following the Forward Split the Company has 40,504,391 shares issued and outstanding.&nbsp;</FONT>&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">During
  our fiscal year ended September 30, 2017, the Company formed three subsidiaries in the state of Nevada: NuLife BioMed, Inc. (&ldquo;NuLife
  BioMed&rdquo;), NuLife Technologies, Inc. (&rdquo;NuLife Technologies&rdquo;) and NuLife Medical Inc., (&ldquo;NuLife Medical&rdquo;),
  and one in the state of Wyoming: , NuLife Oncology LLC, a Wyoming Limited Liability Company (&ldquo;NuLife Oncology&rdquo;), the
  Managing Member of which is NuLife Technologies NuLife BioMed was the only active subsidiary during the first fiscal quarter ended
  December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">On January 29,
  2017, the Company announced the completion of an Asset Purchase Agreement to acquire all of the assets (the &ldquo;Asset Purchase&rdquo;)
  of GandTex LLC, a Texas Limited Liability Company (&ldquo;GandTex&rdquo;). GandTex is a biomedical company focused on advancing
  human organ transplant technology and medical research. The assets being transferred pursuant to the Asset Purchase consisted of
  certain proprietary patents&nbsp;for&nbsp;eliminating the need for an organ or tissue match, and the necessity for anti-rejection
  drugs, as well as management of, and historical data for, animal trials (&ldquo;Animal Trials&rdquo;) conducted by GandTex(collectively,
  the &ldquo;GandTex Assets&rdquo;). Pursuant to the terms of the Asset Purchase, and upon achieving certain pro-forma goals, the
  Company agreed to provide additional funding for the Trials in the aggregate amount of $300,000. In exchange for the GandTex Assets,
  the Company issued to GandTex 10,000,000 shares of its Series B Convertible Preferred Stock. GandTex is owned and controlled by
  a single individual Managing Member who beneficially owns 70% of GandTex The Asset Purchase was amended by an Addendum to the Asset
  Purchase Agreement effective July 11, 2017, and subsequently restructured so as to perfect ownership of the GandTex Assets by way
  of the GandTex Restructuring Agreements effective July 27, 2017 between GandTex and Duplitrans Inc. (&ldquo;Duplitrans&rdquo;),
  and as to certain of the agreements, the Company. In late October 2017, the Company terminated the Asset Purchase and the GandTex
  Restructuring Agreements on October 24, 2017 in an unwinding of the Asset Purchase by way of a Settlement an Release Agreement
  dated October 24, 2017, involving the full return of the 10,000,000 shares of the Company&rsquo;s Series B Convertible Preferred
  Stock in exchange for a full release of any and all claims that Duplitrans or GandTex may have had against the Company, and the
  transfer of the patents contained within the GandTex Assets to GandTex, and the Exclusive License to Duplitrans, and we entered
  into a Memorandum of Understanding with NuGenesis, a new entity being formed by certain shareholders of Duplitrans, with the intent
  to continue the development of the Wound Care technique in concert with NuGenesis. On December 29, 2017, the Company issued 2,000,000
  common shares which 1,960,000 common shares were issued to Duplitrans and 40,000 common shares were issued to the legal counsel
  of Duplitrans in regards to the agreement with GandTex. On the date of the settlement, October 24, 2017, the shares had a fair
  market value of $640,000. Accordingly, the Company recorded $640,000 of stock based compensation during the three months ended
  December 31, 2017. Refer to NOTE 4 &ndash; Asset Purchase Agreement.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Basis of Presentation</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The Company's
  financial statements are prepared using the accrual method of accounting. The Company elected a September 30 fiscal year-end. These
  financial statements present the consolidated financial statements of NuLife Sciences, Inc. and its two wholly owned subsidiaries,
  NuLife Biomed, NuLife Technologies, an NuLife Medical, along with NuLife Oncology, of which NuLife Technologies is the Managing
  Member, as of the Company&rsquo;s fiscal quarter ended December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 7 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">NuLife Technologies,
  Inc., NuLife Medical and NuLife Oncology were all inactive at December 31, 2017 and remain inactive as of the date of this report.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The unaudited
  interim financial statements have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission.
  The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are,
  in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information
  and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally
  accepted in the United States of America have been omitted pursuant to such rules and regulations. These condensed consolidated
  financial statements should be read in conjunction with the audited financial statements and notes for the year ended September
  30, 2017 included in our Annual Report on Form 10-K. The results of the three-month period ended December 31, 2017 are not necessarily
  indicative of the results to be expected for the full year ending September 30, 2018.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;<B>Cash Equivalents</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">For purposes of
  the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with maturity of three months
  or less at the time of issuance to be cash equivalents. The Company does not have any cash equivalent as of December 31, 2017 and
  September 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stock-based Compensation</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The Company
  follows ASC 718-10,&nbsp;<I>Stock Compensation</I>, which addresses the accounting for transactions in which an entity
  exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains
  employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services
  received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited
  exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be
  recognized Nonemployee share-based payments are measured at fair value, based on either the fair value of the equity
  instrument issued or on the fair value of the services received. We determine the fair value of common stock grants based on
  the price of the common stock on the measurement date (which is the earlier of the date at which a commitment for performance
  by the counterparty to earn the equity instruments is reached, if there are sufficient disincentives to ensure performance,
  or the date at which the counterparty's performance is complete). We determine the fair value of preferred stock grants based
  on the price of the preferred stock as potentially converted into common stock and based on the underlying common stock on
  the measurement date (which is the earlier of the date at which a commitment for performance by the counterparty to earn the
  equity instruments is reached, if there are sufficient disincentives to ensure performance, or the date at which the
  counterparty's performance is complete).</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Use of Estimates and Assumptions</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Preparation of
  the financial statements in conformity with accounting principles generally accepted in the United States requires management to
  make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from
  those estimates. The Company has adopted the provisions of ASC 260.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Management makes estimates that affect
  certain accounts including, deferred income tax, accrued expenses, fair value of equity instruments and reserves for any other
  commitments or contingencies. Any adjustments applied to estimates are recognized in the year in which such adjustments are determined.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Loss per Share</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The basic loss
  per share is calculated by dividing the Company's net loss available to common shareholders by the weighted average number of common
  shares during the year. The diluted loss per share is calculated by dividing the Company's net loss available to common shareholders
  by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding
  is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. Diluted loss per share are the same
  as basic earnings loss per share due to the lack of dilutive items in the Company.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 8 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Fair Value Measurements and Disclosures</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Fair value estimates
  discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31,
  2017 and September 30, 2017. The respective carrying value of certain on-balance-sheet financial instruments, approximate their
  fair values. These financial instruments include cash, accounts receivable, accounts payable, accrued expenses and notes payable.
  Fair values were assumed to approximate carrying values for these financial instruments because they are short term in nature and
  their carrying amounts approximate fair values or they are receivable or payable on demand.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company uses
  fair value measurements under the three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure
  for fair value measures. The three levels are defined as follows:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 4%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&nbsp;inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&nbsp;inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&nbsp;inputs to the valuation methodology are unobservable and significant to the fair value.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
      <TD COLSPAN="3" STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="11" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair Value Measurements&nbsp;</B></FONT><BR>
  <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Using Fair Value Hierarchy</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD COLSPAN="3" STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level 1</B></FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level 2</B></FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level 3</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 60%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes (net of discount) &ndash; December 31, 2017</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 10%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 10%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106,557</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes (net of discount) &ndash; September 30, 2017</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,459</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability &ndash; December 31, 2017</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,559</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability &ndash; September 30, 2017</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">231,733</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
  provides a summary of the changes in fair value of the Company&rsquo;s Convertible Promissory Notes, which are both Level 3 liabilities
  as of December 31, 2017:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 70%">Balance at September 30, 2017</TD><TD STYLE="width: 10%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">81,459</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>Issuance of notes</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Accretion of debt discount</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,617</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Debt discount on convertible notes due to beneficial conversion feature</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,667</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Accretion of debt discount due to beneficial conversion feature</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,148</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Payment of convertible debt</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(78,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left; padding-bottom: 1pt">Conversion of principal into shares of common stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(75,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-bottom: 2.5pt">Balance December 31, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">106,557</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company determined
  the value of its convertible notes using a market interest rate and the value of the derivative liability issued at the time of
  the transaction less the accretion. There is no active market for the debt and the value was based on the delayed payment terms
  in addition to other facts and circumstances at the end of December 31, 2017 and September 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company determined
  the value of warrants issued to a consultant using the Black-Scholes Model. There is no active market for the warrants and the
  value was based on the warrant terms in addition to other facts and circumstances at the end of the Company&rsquo;s first quarter
  ended December 31, 2017 and its fiscal year ended September 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Derivative Financial Instruments</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company evaluates
  our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
  For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at
  its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
  For stock-based financial instruments, the Company uses the Black-Scholes-Merton pricing model to value the derivative instruments.
  The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity,
  is evaluated</P>
  
  
  <!-- Field: Page; Sequence: 9 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">at the end of each reporting period.
  Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash
  settlement of the derivative instrument could be required within 12 months of the balance sheet date.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The classification
  of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at
  the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value
  of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current
  or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet
  date.&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company estimates
  the fair value of these instruments using the Black-Scholes option pricing model and the intrinsic value if the convertible notes
  are due on demand.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have determined
  that certain convertible debt instruments outstanding as of the date of these financial statements include an exercise price &ldquo;reset&rdquo;
  adjustment that qualifies as derivative financial instruments under the provisions of ASC 815-40, Derivatives and Hedging - Contracts
  in an Entity&rsquo;s Own Stock (&ldquo;ASC 815-40&rdquo;). Certain of the convertible debentures have a variable exercise price,
  thus are convertible into an indeterminate number of shares for which we cannot determine if we have sufficient authorized shares
  to settle the transaction with. Accordingly, the embedded conversion option is a derivative liability and is marked to market through
  earnings at the end of each reporting period. Any change in fair value during the period recorded in earnings as &ldquo;Other income
  (expense) - gain (loss) on change in derivative liabilities.&rdquo; Please refer to Note 8 below.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Income Taxes</B></P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Income taxes are
  provided in accordance with ASC 740,&nbsp;<I>Income Taxes</I>. A deferred tax asset or liability is recorded for all temporary
  differences between financial and tax reporting and net operating loss carry forwards. Deferred tax expense (benefit) results from
  the net change during the year of deferred tax assets and liabilities.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Deferred tax assets
  are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of
  the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax
  laws and rates on the date of enactment.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">No provision was
  made for Federal or State income taxes.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Advertising</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Advertising will
  be expensed in the period in which it is incurred. There have been no advertising expenses for the reporting periods presented.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Intangible Assets</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Intangible assets
  with finite lives are amortized over their estimated useful life. The Company monitors conditions related to these assets to determine
  whether events and circumstances warrant a revision to the remaining amortization period. The Company tests its intangible assets
  with finite lives for potential impairment whenever management concludes events or changes in circumstances indicate that the carrying
  amount may not be recoverable. The original estimate of an asset's useful life and the impact of an event or circumstance on either
  an asset's useful life or carrying value involve significant judgment.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Research and Development</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research is planned
  search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing
  a new product or service (hereinafter &ldquo;product&rdquo;) or a new process or technique (hereinafter &ldquo;process&rdquo;)
  or in bringing about a significant improvement to an existing product or process. Development is the translation of research findings
  or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or
  process whether intended for sale or use. It includes the conceptual formulation, design, and testing of product alternatives,
  construction of prototypes, and operation of pilot plants. It does not include routine or periodic alterations to existing products,
  production lines, manufacturing processes, and other on-going operations even though those alterations may represent improvements
  and it does not include market research or market testing activities. Per ASC 730, the Company expenses research and development
  cost as incurred.</P>
  
  <!-- Field: Page; Sequence: 10 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recently Issued Accounting Pronouncement</B>s</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">In February 2016,
  the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840).
  ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves accounting for the lessor largely unchanged.
  The amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal
  years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing
  at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company
  is currently evaluating the impact of this new standard on its consolidated financial statements.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">In March 2016,
  the Financial Accounting Standards Board (&quot;FASB&quot;) issued Accounting Standards Update (&quot;ASU&quot;) No. 2016-09, &ldquo;Compensation
  - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&rdquo; (&ldquo;ASU 2016-09&rdquo;). The
  standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax
  impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods
  within those years, beginning after December 15, 2016, and early adoption is permitted. The Company has adopted this new standard.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">In January 2017,
  the FASB issued Accounting Standards Update No. 2017-01,&nbsp;<I>Business Combinations (Topic 805): Clarifying the Definition of
  a Business&nbsp;</I>(ASU 2017-01), which revises the definition of a business and provides new guidance in evaluating when a set
  of transferred assets and activities is a business. This guidance will be effective for the Company in the first fiscal quarter
  of 2018 on a prospective basis, and early adoption is permitted. The Company does not expect the standard to have a material impact
  on our consolidated financial statements.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">In July 2017,
  the Financial Accounting Standards Board (&quot;FASB&quot;) issued Accounting Standards Update 2017-11 (&ldquo;ASU 2017-11&rdquo;)
  which changes the accounting for equity instruments that include a down round feature.&nbsp; For public entities, this update is
  effective for fiscal years beginning after December 15, 2018, and interim periods within those years.&nbsp; Early adoption is permitted.
  &nbsp;The Company does not anticipate the adoption of this amendment will have an impact on the consolidated financial statements&nbsp;and
  related disclosures as the Company does not have any related equity instruments.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company reviewed
  all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC and
  they did not or are not believed by management to have a material impact on the Company's present or future financial statements.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 3 &ndash; GOING CONCERN</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying
  consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the three
  months ended December 31, 2017, the Company had a net loss of $878,158. As of December 31, 2017, the Company had a working capital
  deficit of $1,080,211 and an accumulated deficit of $7,483,763. The Company does not have a source of revenue and does not anticipate
  having one in the near future. Without additional capital, the Company will not be able to remain in business within the next twelve
  months.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These factors raise
  a substantial doubt about the Company&rsquo;s ability to continue as a going concern. The accompanying financial statements do
  not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts
  and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management has plans
  to address the Company&rsquo;s financial situation as follows:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">In the near term,
  management plans to continue to focus on raising the funds necessary to implement the Company&rsquo;s business plan. Management
  will continue to seek out debt financing to obtain the capital required to meet the Company&rsquo;s financial obligations. There
  is no assurance, however, that lenders will advance capital to the Company or that the new business operations will be profitable.
  The Company&rsquo;s future plans is fully dependent upon the funding of NuGenesis sufficient to carry forward the research on the
  Wound Care Process, and upon the ability of Duplitrans to also obtain sufficient funding to continue with the development of the
  NuLife Process at the Company&rsquo;s existing facilities.</P>
  
  <!-- Field: Page; Sequence: 11 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The possibility of failure in obtaining additional
  funding and the potential inability to achieve profitability raise doubts about the Company&rsquo;s ability to continue as a going
  concern.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">In the long term,
  management believes that the Company&rsquo;s projects and initiatives will be successful and will provide cash flow to the Company,
  which will be used to finance the Company&rsquo;s future growth. However, there can be no assurances that the Company&rsquo;s planned
  activities will be successful, or that the Company will ultimately attain profitability. The Company&rsquo;s long-term viability
  depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation
  of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to
  sustain its operations. Substantial doubt has not been alleviated from management&rsquo;s plan at this time.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 4 &ndash; ASSET PURCHASE AGREEMENT</B></P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; background-color: white">Following
  the Closing of the Asset Purchase, in March 2017, we learned that Mr. James Gandy did not have proper authority to transfer the
  Exclusive License rights from Duplitrans to GandTex, after which we proposed a restructuring of the transaction, which was approved
  by the Duplitrans shareholders, so that we ended up with exclusive use and ownership of the intellectual property that was in dispute,
  but at the same time the Duplitrans shareholders were compensated for the license termination by way of an amendment to the conversion
  terms of the Series B Preferred Stock and a Royalty Agreement in favor of Duplitrans (the &ldquo;GandTex Restructuring&rdquo;).</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">Following
  our initial stage of the resumption of the Animal Trials conducted earlier in Ecuador by Duplitrans and GandTex, and the GandTex
  Restructuring, we learned that certain critical information concerning the organ transplantation process, thought to be contained
  in the GandTex Assets, was not contained in any of the Patents or License comprising the GandTex Assets, and was withheld by the
  inventor, Mr. Gandy during his review of our Protocol for the transplantation procedures (the &ldquo;Omitted Transplantation Information&rdquo;).
  In October 2017, as described in our Form 8-K filed October 21, 2017 following the discovery of the Omitted Transplantation Information,
  we entered into a settlement agreements with Duplitrans and GandTex pursuant to which we reversed the Asset Acquisition and the
  GandTex Restructuring Agreements in their entirety, and GandTex and Duplitrans agreed to the full return of the 10,000,000 shares
  of our Series B Preferred Stock, the cancellation of the Royalty Agreement with Duplitrans/GandTex, and a full release by GandTex
  and Duplitrans from any and all claims that they may have believed they had against us (the &ldquo;Release&rdquo;). In consideration
  for the termination of the Asset Purchase Agreement and the GandTex Restructuring Agreements, the Release and the return of our
  Series B Preferred Stock, we issued 2,000,000 shares of our common Stock to Duplitrans and to Duplitrans legal counsel.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">In conjunction
  with Mr. Gandy&rsquo;s final disclosure of the Omitted Transplantation Information, but prior to the Release and unwinding of the
  Asset Purchase, we entered into a Memorandum of Understanding (the &ldquo;MOU&rdquo;) with NuGenesis, an entity in formation organized
  by certain of the Duplitrans shareholders (&ldquo;NuGenesis&rdquo;), which we believed could enable us to continue to pursue the
  Animal Studies and a secondary application of the NuLife Process &ndash; known as the &ldquo;Wound Care Technique&rdquo;.</P>
  
  <P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">To
  date, the proposed Wound Care activities (the &ldquo;Wound Care Technique&rdquo;) are still in the investigation stage, without
  significant expenditures by the Company due to our efforts to maintain adequate funding for our corporate operations. The commercial
  relationship between the NuGenesis and Duplitrans has not yet been established in an adequate definitive joint venture agreement,
  but only through the MOU during this exploratory stage of the business. Neither the Company or NuGenesis currently have the necessary
  funding to resume the development of the Wound Care Technique, and the reduction of the MOU to a definitive agreement is contingent
  upon either the Company or NuGenesis obtaining the funding necessary to carry the proposed development through to completion</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE&nbsp;5 - CONSULTING AGREEMENTS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 1, 2015,
  the Company entered into a twelve-month consulting agreement with an investor relations firm. Per the agreement, the Company will
  pay the consultant a monthly fee of $8,500 on the first day of each month with the payment deferred until the Company closes financing
  in the amount of $3 million or greater. Additionally, the Company was required to issue the consultant 200,000 shares of common
  stock on October 1, 2015. The agreement was terminated on October 16, 2016. During the three months ended December 31, 2017 and
  2016, the Company recorded compensation expense in the amount of $-0- and $2,133 related to this agreement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 12 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="background-color: white">On
  February 28, 2017, but effective January 5, 2017, the Company entered into an Advisory Agreement with Global Business Strategies
  Inc. (&ldquo;Global &ldquo;), a company controlled Mr. Luke (the &ldquo;Global Agreement&rdquo;). Pursuant to the Global Agreement
  the Company retained Global to provide management advice, corporate development strategies, to </FONT>assist in the general and
  administrative functions<FONT STYLE="background-color: white">, and to make Mr. Luke available to serve as a Director or a member
  of the Company&rsquo;s management (the &ldquo;Services&rdquo; as defined in the Global Agreement).&nbsp; In consideration for the
  Services the Company agreed to pay Global $8,500 per month, which included any and all fees for Mr. Luke continuing to serve as
  the Company&rsquo;s President and fees to others working for Global, and allowed for reimbursement of expenses up to $500 per month
  without prior written approval. The Company also agreed to pay Global an additional $1,500 per month if Mr. Luke was appointed
  to serve as a Director also incorporated you of the Company, and agreed to issue to Global </FONT>55,000 shares of its Series A
  Convertible Preferred Stock. Mr. Luke has not been appointed a Director of the Company as of the date of this report. During the
  three months ended December 31, 2017 and 2016, the Company recorded compensation expense in the amount of $25,500 and $-0- related
  to this agreement.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 10, 2017,
  the Company entered into a Master Service Agreement with an investment consultant to provide services to the Company for a period
  of six months. The agreement calls for a budget of $215,000 with an initial payment of $150,000. Additionally, the agreement called
  for the issuance of 250,000 cashless warrants exercisable for three years at a price of 110% of the closing price on June 10, 2017.
  The Company paid $65,000 of the initial payment on August 14, 2017, the remaining $85,000 of the initial payment and $65,000 of
  the balance of the agreement, for a total of $150,000 is included in accounts payable as of December 31, 2017 and September 30,
  2017. See Note 13&ndash; Subsequent Events.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 6 &ndash; NOTES PAYABLE</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of December
  31, 2017, the Company had a note payable issued and outstanding to a third-party lender with a total principle of $25,000 and accrued
  interest of $15,912. The note was due on June 30, 2015, has an interest rate of 12%. This note is in default and remains unpaid
  at December 31, 2017. The Company has been able in the past to arrange equity or debt financing sufficient to pay off its notes,
  not in dispute, but there cannot be any assurance that the Company will be able to continue to attract such financing in the future.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31,
  2017, the Company had three notes payable issued and outstanding with a former director with a total principle of $74,500 and accrued
  interest of $14,366. The three notes, in the amount of $47,000, $15,000 and $12,500, were issued on January 14, 2016. February
  10, 2016 and February 29, 2016, respectively. The three notes are due on the earlier of one week after the closing of a certain
  contemplated farm property acquisition or July 31, 2016, and have an interest rate of 10%. The former director for all three notes
  is East West Secured Developments, LLC, an Arizona Limited Liability Company (&ldquo;EWSD&rdquo;) of which Mr. Brian Loiselle,
  the EWSD Managing Member, was also a former director of the Company. On June 30, 2016, the Company entered into Amendment #1 (the
  &ldquo;EWSD Amendment&rdquo;) to these three notes to extend the due date to one week after the closing of a certain contemplated
  farm property acquisition or October 31, 2016. The three notes have been reclassified to non-related party debt. Since the closing
  of the contemplated farm property never occurred, the Company has taken the position, pursuant to the language of the EWSD Amendments,
  that there is not legal date for repayment, and it intends to leave the subject notes on its Financial Statements until a mutual
  settlement agreement can be reached between Mr. Loiselle and the Company.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 28,
  2017, the Company entered into a note payable in the aggregate principal amount of $106,410. The Note matures on March 31, 2018,
  and bears interest at the rate of 12% per annum. As of December 31, 2017, the note balance and accrued interest is $106,410 and
  $105, respectively. This note remains unpaid at December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>
  
  <!-- Field: Page; Sequence: 13 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 7 &ndash; CONVERTIBLE NOTES</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Convertible notes consist of the following:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30,<BR> 2017</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 63%; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible note payable, annual interest rate of 8%, convertible into common stock at $0.11 per share and due December 2019.</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">80,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible
      note payable, annual interest rate of 12%, convertible into common stock at a variable rate per share and due June 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">78,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible note payable, annual interest rate of 8%, convertible into common stock at a variable rate per share and due November 2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">65,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">65,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible note payable, annual interest rate of 8%, convertible into common stock at $0.11 per share and due August 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible note payable, annual interest rate of 5%, convertible into common stock at a variable rate per share and due September 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">82,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">82,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible note payable, annual interest rate of 8%, convertible into common stock at $0.30 per share and due October 13, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unamortized debt discount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(56,864</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(91,480</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount due to beneficial conversion feature</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(59,079</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(-)</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">106,557</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">81,459</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">92,380</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">58,432</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible debt, net of current portion and debt discount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,177</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year
  ended September 30, 2017, the Company entered into certain Note Purchase Agreements (collectively the &ldquo;Purchase Agreements&rdquo;)
  in connection with the issuance of certain convertible promissory notes, in the aggregate principal amount of $685,000. The Purchase
  Notes are due in 36 months. The Purchase Notes bear interest at the rate of 8% compounded monthly. The Purchase Notes, together
  with all interest as accrued, are each convertible into shares of the Company&rsquo;s common stock at a conversion price of Eleven
  cents ($0.11) per share. Due to the beneficial conversion feature of these notes, the Company recorded $635,545 of debt discount
  as a contra liability and amortized $576,838 of the discount during the year ended September 30, 2017. During July 2017, certain
  note holders converted their respective principal and accrued interest into 5,720,066 shares of the Company&rsquo;s common stock.
  During October 2017, certain note holders converted their respective principal and accrued interest into 707,153 shares of the
  Company&rsquo;s common stock. As of December 31, 2017, the note balances and accrued interest are $5,000 and $419, respectively.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 26, 2017,
  the Company entered into a Securities Purchase Agreement (&ldquo;SAP&rdquo;) in connection with the issuance of a convertible promissory
  note (the &ldquo;Power Up Note&rdquo;) in the aggregate principal amount of $78,000. The Power Up Note matures on June 30, 2018
  (the &ldquo;Maturity Date&rdquo;), and bears interest at the rate of 12% per annum. After 180 days, the Note may not be prepaid.
  Any amount of principal or interest on this note which is not paid when due shall bear interest at the rate of twenty two percent
  (22%) per annum from the due date. This note, together with all interest as accrued, is convertible into shares of the Company&rsquo;s
  common stock at a 35% discount to the lowest trading price in the 10-day period ending on the latest complete Trading Day prior
  to the Conversion Date. Due to the beneficial conversion feature of this note, the Company recorded $78,000 of debt discount as
  a contra liability and amortized $57,707 of the discount during the three months ended December 31, 2017. During the quarter ended
  December 2017, this note along with accrued interest and a prepayment were paid in full.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 14, 2017,
  the Company entered into a Securities Purchase Agreement (&ldquo;SAP&rdquo;) in connection with the issuance of a convertible promissory
  note (the &ldquo;Kingdom Note&rdquo;) in the aggregate principal amount of $65,000. The Note matures on November 14, 2017 (the
  &ldquo;Maturity Date&rdquo;), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued,
  is convertible into shares of the Company&rsquo;s common stock at $0.11 per share. Due to the beneficial conversion feature of
  this note, the Company recorded $65,000 of debt discount as a contra liability and amortized $31,056 of the discount during the
  three months ended December 31, 2017. As of December 31, 2017, the note balance and accrued interest is $65,000 and $1,995, respectively.
  This note is in default and remains unpaid at December 31, 2017, however, the Company and the Payee entered into a Debt Conversion
  Agreement in February, 2018 pursuant to which the Payee received shares of the Company&rsquo;s Series A Convertible Preferred Stock
  in exchange for the full release of any and all obligations related to the Kingdom Note. Refer to NOTE 13. SUBSEQUENT EVENTS.</P>
  
  <!-- Field: Page; Sequence: 14 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 23, 2017,
  the Company entered into a Securities Purchase Agreement (&ldquo;SAP&rdquo;) in connection with the issuance of a convertible
  promissory note (the &ldquo;Hayden Note&rdquo;) in the aggregate principal amount of $50,000. The Note matures on August 23, 2020
  (the &ldquo;Maturity Date&rdquo;), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued,
  is convertible into shares of the Company&rsquo;s common stock at $0.11 per share. Due to the beneficial conversion feature of
  this note, the Company recorded $50,000 of debt discount as a contra liability and amortized $4,197 of the discount during the
  three months ended December 31, 2017. As of December 31, 2017, the note balance and accrued interest is $50,000 and $1,434, respectively.
  This note remains unpaid at December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 12,
  2017, the Company entered into a Securities Purchase Agreement (&ldquo;SAP&rdquo;) in connection with the issuance of a convertible
  promissory note (the &ldquo;First Fire Note&rdquo;) in the aggregate principal amount of $82,500. The Note matures on September
  12, 2018 (the &ldquo;Maturity Date&rdquo;), and bears interest at the rate of 5% per annum. The Note, together with all interest
  as accrued, is convertible into shares of the Company&rsquo;s common stock at a 35% discount to the lowest trading price in the
  21-day period ending on the latest complete Trading Day prior to the Conversion Date. As of December 31, 2017, the note balance
  and accrued interest is $82,500 and $1,243. This note remains unpaid at December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 13, 2017,
  the Company entered into a Securities Purchase Agreement (&ldquo;SAP&rdquo;) in connection with the issuance of a convertible promissory
  note (the &ldquo;Escala Note&rdquo;) in the aggregate principal amount of $20,000. The Note matures on October 13, 2020 (the &ldquo;Maturity
  Date&rdquo;), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued, is convertible into
  shares of the Company&rsquo;s common stock at $0.30 per share. Due to the beneficial conversion feature of this note, the Company
  recorded $12,667 of debt discount as a contra liability and amortized $913 of the discount during the three months ended December
  31, 2017. As of December 31, 2017, the note balance and accrued interest is $20,000 and $346, respectively. This note remains unpaid
  at December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 8 &ndash; DERIVATIVE LIABILITY</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During June 2017,
  the Company entered into a Loan Agreement with an investor pursuant to which the Company issued a convertible promissory note in
  the principal amount of $78,000. The Note is convertible into shares of common stock at an initial conversion price subject to
  adjustment as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company&rsquo;s
  common stock at 65% of the trailing average highest closing bid price of the Company&rsquo;s common stock on the date of conversion.
  The Note accrues interest at a rate of 12% per annum and matures on June 30, 2018. The note was paid in full during the three months
  ended December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During September
  2017, the Company entered into a Loan Agreement with an investor pursuant to which the Company issued a convertible promissory
  note in the principal amount of $82,500. The Note is convertible into shares of common stock at an initial conversion price subject
  to adjustment as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company&rsquo;s
  common stock at 65% of the trailing average highest closing bid price of the Company&rsquo;s common stock on the date of conversion.
  The Note accrues interest at a rate of 5% per annum and matures on September 12, 2018.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the variable
  conversion price associated with these convertible promissory notes, the Company has determined that the conversion feature is
  considered a derivative liability. The accounting treatment of derivative financial instruments requires that the Company record
  the fair value of the derivatives as of the inception date of the Convertible Promissory Note and to adjust the fair value as of
  each subsequent balance sheet date.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 15 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The initial fair
  value of the embedded debt derivative of $238,785 was allocated as a debt discount in the amount of $147,500 and excess $91,285
  was charged to interest expenses, loss on derivative. The fair value of the described embedded derivative was determined using
  the Black-Scholes Model with the following assumptions:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font-size: 11pt">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 12, 2017</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2017</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="width: 39%">(1) dividend yield of</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 28%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%;</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 28%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%;</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>(2) expected volatility of</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">265%;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250%,</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">(3) risk-free interest rate of</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27%;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20% - 1.24%,</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>(4) expected life of</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 year</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 year</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">(5) fair value of the Company&rsquo;s common stock of</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.54 per share.</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.67 per share.</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the three
  months ended December 31, 2017 and 2016, the Company recorded the gain (loss) in fair value of derivative and derivative expense
  in the amount of $61,221 and $(14,319), respectively.&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the three months
  ended December 31, 2017, $79,148 and $-0-, were expensed in the statement of operation as amortization of debt discount related
  to above notes and shown as interest expenses, respectively.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
  represents the Company&rsquo;s derivative liability activity for the period ended:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 79%">Balance at September 30, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">231,733</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Change in fair value of derivative at period end</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61,221</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left; padding-bottom: 1pt">Derivative liability written off due to payment of related debt</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(67,953</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-bottom: 2.5pt">Balance at December 31, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">102,559</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 9 &ndash; SHARE CAPITAL</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The Company is
  authorized to issue 475,000,000 shares of $.001 par value common stock and 25,000,000 shares of$.001 par value preferred stock.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of December
  31, 2017, the Company had 40,504,391 shares of its common stock issued and outstanding, with 117,500 shares of its Series A Convertible
  Preferred Stock issued and outstanding and -0- shares of its Series B Convertible Preferred Stock issued and outstanding..</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">On December 29,
  2017, the Company issued 2,000,000 to Duplitrans and the legal counsel of Duplitrans in regards to the agreement with GandTex.
  On the date of the settlement, October 24, 2017, the shares had a fair market value of $640,000. Accordingly, the Company recorded
  $640,000 of stock based compensation during the three months ended December 31, 2017. All of the Company&rsquo;s 10,000,000 Series
  B Convertible Preferred Stock, previously issued to GandTex, were cancelled during the quarter ended December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Description of Preferred Stock:</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Series A Preferred
  Stock</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">As
                                           authorized in the Company&rsquo;s Amended and Restated Articles of Incorporation, the
                                           Company has 2,000,000 shares of Series A Preferred Stock (&ldquo;Series A Stock&rdquo;)
                                           authorized with the following characteristics:</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
                                           of the Series A Stock shall be entitled to receive dividends or other distributions with
                                           the holders of the Common Stock on an &ldquo;as converted&rdquo; basis when, as, and
                                           if declared by the Directors of the</FONT><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporation.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 16 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Holders
                                           of shares of Series A Stock, upon Board of Directors approval, may convert at any time
                                           following the issuance upon sixty-one (61) day written notice to the Corporation. Each
                                           share of Series A Preferred Stock shall be convertible into such number of fully paid
                                           and non-assessable shares of Common Stock as is determined by multiplying the number
                                           of issued and outstanding shares of the Corporation&rsquo;s Common Stock together with
                                           all other derivative securities, including securities convertible into or exchangeable
                                           for Common Stock, whether or not then convertible or exchangeable (b) subscriptions,
                                           rights, options and warrants to purchase shares of Common Stock, whether or not then
                                           exercisable, but entitled to vote on matters submitted to the Shareholders (collectively,
                                           &ldquo;Derivative Securities&rdquo;), issued by the Corporation and outstanding as of
                                           the Date of Conversion, by .000001, then multiplying that number of shares of Series
                                           A Stock to be converted.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                           case of any consolidation or merger of the Corporation, the Corporation shall mail to
                                           each holder of Series A Stock at least thirty (30) days prior to</FONT><FONT STYLE="font-family: SimSun; font-size: 10pt">&#12288;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                           consummation of such event, a notice thereof and each such holder shall have the option
                                           to either (i) convert such holder&rsquo;s shares of Series A Stock into shares of Common
                                           Stock pursuant to this paragraph and thereafter receive the number of shares of Common
                                           Stock or other securities or property, or cash, as the case may be, to which a holder
                                           of the number of shares of Common Stock of the Corporation deliverable upon conversion
                                           of such Series A Stock would have been entitled upon conversion immediately preceding
                                           such consolidation, merger or conveyance, or (ii) exercise such holder&rsquo;s rights
                                           pursuant to Section 8.1(a) hereof; provided however that the Series A Stock shall not
                                           be subject to or affected as to the number of Conversion Shares or the redemption or
                                           liquidation price by reason of any reverse stock split affected prior or as a result
                                           of any reorganization.</FONT></TD></TR></TABLE>
  
  
  
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In
                                           the event of a liquidation, the holders of shares of the Series A Stock shall be entitled
                                           to receive, prior to the holders of the other series of Preferred Stock and prior and
                                           in preference to any distribution of the assets or surplus funds of the Corporation to
                                           the holders of any other shares of stock of the Corporation by reason of their ownership
                                           of such stock, an amount equal to Five Dollar ($5.00) per share with respect to each
                                           share of Series B Stock owned as of the date of Liquidation, plus all declared but unpaid
                                           dividends with respect to such shares, and thereafter they shall share in the net Liquidation
                                           proceeds on an &ldquo;as converted basis&rdquo; on the same basis as the holders of the
                                           Common Stock.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                           holders of each share of Series A Stock shall have that number of votes as determined
                                           by multiplying the number of issued and outstanding shares of the Corporation&rsquo;s
                                           Common Stock together with all other derivative securities issued by the Corporation
                                           and outstanding as of the Date of Conversion, whether or not then convertible or exchangeable,
                                           entitled to vote on matters submitted to the Shareholders, by .000001, then multiplying
                                           that number of shares of Series A Stock to be converted.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the
                                           Corporation shall have the option to redeem all of the outstanding shares of Series A
                                           Stock at any time on an &ldquo;all or nothing&rdquo; basis, unless otherwise mutually
                                           agreed in writing between the Corporation and the holders of shares of Series A Stock
                                           holding at least 51% of such Series A Stock, beginning ten (10) business days following
                                           notice by the Corporation, at a redemption price the higher of (a) Five Dollar ($5.00)
                                           per share, or (b) Fifty percent (50%) of the trailing average highest closing Bid price
                                           of the Corporation&rsquo;s Common Stock as published at www.OTCMarkets.com or the Corporation&rsquo;s
                                           primary listing exchange on the date of Notice of redemption, unless otherwise modified
                                           by mutual written consent between the Corporation and the Holders of the Series A Stock
                                           (the &quot;Conversion Price&quot;). Redemption payments shall only be made in cash within
                                           sixty (60) days of notice by the Corporation to redeem.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                           shares of Series A Stock acquired by the Corporation by reason of conversion or otherwise
                                           can be reissued, but only as an amended class, not as shares of Series A Stock.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <!-- Field: Page; Sequence: 17 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Series
  B Preferred Stock</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In
                                           conjunction with the unwinding of the Asset Acquisition with GandTex, the Company cancelled
                                           all 10,000,000 shares of its Series B Preferred Stock (&ldquo;Series B Stock&rdquo;).
                                           Pursuant to the terms of the Series B Stock, the shares of Series B Stock acquired by
                                           the Corporation by reason of conversion or otherwise, can be reissued but only as an
                                           amended class, not as shares of Series B Stock. </FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">Therefore, the Company returned
  the Series B Stock to its authorized but unissued Preferred Stock and no longer has a class of Series B Convertible Preferred Stock.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 1pt 0 0; background-color: white"><B><U>Stock Options</U></B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 15,
  2016, the Board approved the grant of 1,500,000 common stock purchase options to Fred Luke, the Company&rsquo;s President, at an
  exercise price of not less than One Hundred Ten percent (110%) of the ten (10) day lowest trailing average closing bid price of
  such shares on the date of execution of the Option Agreement which was Fourteen cents ($0.14) per share and subject to certain
  adjustments on November 15, 2016. The options vested immediately.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 31,
  2017, the Board approved the grant of 120,000 common stock purchase options Dr. Youxue Wang, the Director of Research for NuLife
  BioMed. The option vested immediately. The exercise price of the options was calculated at January 31, 2017 at One Hundred Ten
  percent (110%) of the 10-day trailing average closing Bid price of such shares, which was Seventy cents ($0.70) per share.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 15, 2017,
  the Board approved the grant of 1,500,000 common stock purchase options to John Hollister, the Company&rsquo;s former CEO, at an
  exercise price of not less than One Hundred Ten percent (110%) of the ten (10) day lowest trailing average closing bid price of
  such shares on a certain date of agreement which was Fourteen cents ($0.12) per share and subject to certain adjustments on October
  17, 2016. The options vested based on certain goals and as such 500,000 common stock options were earned prior to Mr. Hollister&rsquo;s
  employment ending with the Company, the remaining 1,000,000 common stock options expired due to his resignation.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">Stock option transactions for the
  three months ended December 31, 2017 are summarized as follows:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Weighted </B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Average</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exercise</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Price</B></P></TD>
      <TD NOWRAP STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Weighted </B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Average </B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Remaining</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Term</B></P></TD>
      <TD NOWRAP STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Aggregate</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Intrinsic Value</B></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="width: 41%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding, September 30, 2017</B></FONT></TD>
      <TD STYLE="width: 1%; text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 12%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,120,000</FONT></TD>
      <TD NOWRAP STYLE="width: 2%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 14%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17</FONT></TD>
      <TD NOWRAP STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 10%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.26</FONT></TD>
      <TD NOWRAP STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 13%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">355,200&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 1pt; line-height: 115%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,000,000)</FONT></TD>
      <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.12</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.08&nbsp;</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,000&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding, December 31, 2017</B></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,120,000</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">355,200</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, December 31, 2017</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,120,000</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">355,200</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The initial fair
  value of the options was $308,909 charged to operating expense during the year ended September 30, 2017. The fair value of the
  option was determined using the Black-Scholes Model with the following assumptions:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: bottom; width: 63%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) dividend yield of</FONT></TD>
      <TD STYLE="vertical-align: top; width: 2%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 34%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%;</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) expected volatility of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">236%,313%,223%</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) risk-free interest rate of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28%,1.46%,.98%</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) expected life of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years, and</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) fair value of the Company&rsquo;s common stock of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.13, $0.60, $0.11 per share.</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 18 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><B><U>Warrants</U></B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 10, 2016,
  the Board approved the grant of 250,000 common stock purchase warrants to a consultant at an exercise price of not less than One
  Hundred Ten percent (110%) of the ten (10) day lowest trailing average closing bid price of such shares on the date of execution
  of the warrant which was $0.66 per share. The warrants vested immediately.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">Warrant transactions for the three
  ended December 31, 2017 are summarized as follows:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Weighted Average</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exercise</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Price</B></P></TD>
      <TD NOWRAP STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Weighted Average Remaining</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Term</B></P></TD>
      <TD NOWRAP STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Aggregate</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Intrinsic Value</B></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="width: 43%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding, September 30, 2017</B></FONT></TD>
      <TD STYLE="width: 1%; text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 8%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</FONT></TD>
      <TD NOWRAP STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 8%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66</FONT></TD>
      <TD NOWRAP STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 8%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.70</FONT></TD>
      <TD NOWRAP STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 24%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 1pt; line-height: 115%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD NOWRAP STYLE="line-height: 115%; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding, December 31, 2017</B></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.44</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, December 31, 2017</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.44</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The initial fair
  value of the options was $144,800 charged to operating expense during the year ended September 30, 2017. The fair value of the
  option was determined using the Black-Scholes Model with the following assumptions:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: bottom; width: 62%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) dividend yield of</FONT></TD>
      <TD STYLE="vertical-align: top; width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 36%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%;</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) expected volatility of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">249%</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) risk-free interest rate of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5%</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) expected life of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years, and</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) fair value of the Company&rsquo;s common stock of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.60 per share.</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
  Company recorded $-0- and $186,904 of stock compensation expense in the statements of operations for the three months ended December
  31, 2017 and 2016, respectively, related to non-vested share-based compensation arrangements granted under existing stock option
  plans.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt; background-color: white">As
  of December 31, 2017, there was $0 of total unrecognized compensation cost related to non-vested share-based compensation arrangements
  granted under existing stock option plans.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>NOTE 10&nbsp;-
  CONTINGENCY</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31,
  2017, as described in Note 6, the Company has accrued $53,200 in accrued expenses,&nbsp;note payable of $74,500&nbsp;and accrued
  interest of $14,366 due EWSD. At September 30, 2017 the Company owed EWSD the aggregated amount of $138,311, which is past due
  and has been in default since October 31, 2016. On top of the amount accrued by the Company, Mr. Loiselle had demanded for a penalty
  fee of $101,235, which is approximately 18% monthly default rate on the amount past due. We believe the penalty fee imposed is
  invalid and are currently in dispute with Mr. Loiselle. See NOTE 6. above.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>NOTE 11
  &ndash; FORGIVENESS OF ACCOUNTS PAYABLE</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 15,
  2017, a service vendor with a balance due of $73,644 agreed to cancel the debt owed by The Company. Accordingly, the Company recorded
  $73,644 of forgiveness of debt during the three months ended December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B></B></P>
  
  <!-- Field: Page; Sequence: 19 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>NOTE 12&nbsp;-
  LEASE AGREEMENT</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During May 2017,
  the executed a 5-year lease for a laboratory at NOVA Southeastern University at which the Company will be utilizing the NuLife
  Technique to process organs, as well as conducting bench research to better characterize and assess the impact of the technique.
  The lease calls for monthly payments of $2,582, which includes the initial base rent of $1,925 along with applicable taxes and
  shared operating expenses. The lease required a security deposit in the amount of $4,871 and requires a 4% increase in base rent
  annually. Rent expense for three months ended December 31, 2017 and 2016 was $8,225 and $-0-, respectively.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Future minimum lease
  payments are as follows for the years ending:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 61%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2018 (remaining months)</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 35%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,633</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2019</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,344</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2020</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,318</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2021</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,331</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2022</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1pt solid; line-height: 115%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,016</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 2.25pt double; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111,642</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>NOTE 13&nbsp;-
  SUBSEQUENT EVENTS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
  January 30, 2018, the Master Service Agreement as described in note 5 entered into on June 10, 2017 was terminated and the Company
  received a refund of $38,000 in cash.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 20 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective
  February 20, 2018 the Company entered into two Debt Conversions Agreements, one with Kingdom Building Inc.
  (&ldquo;Kingdom&rdquo;) and MZHCI LLC (&ldquo;MZ&rdquo;) pursuant to which Kingdom and MZ agreed to exchange an aggregate of
  approximately $445,296 of combined Notes Payable and Accounts Payable into 694,041 and 1,086,176 shares, respectively, of the
  Company&rsquo;s Series A Convertible Preferred Stock.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_003"></A><B>ITEM 2. MANAGEMENT'S DISCUSSION AND
  ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The information contained in this
  Form 10-Q is intended to update the information contained in our Annual Report on Form 10-K for the year ended September 30, 2017
  and presumes that readers have access to, and will have read, the &quot;Management's Discussion and Analysis of Financial Condition
  and Results of Operations&quot; and other information contained in such Form 10-K. The following discussion and analysis also should
  be read together with our financial statements and the notes to the financial statements included elsewhere in this Form 10-Q.</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Except for historical information,
  the matters discussed in this section are forward looking statements that involve risks and uncertainties and are based upon judgments
  concerning various factors that are beyond the Company's control. Consequently, and because forward-looking statements are inherently
  subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed
  in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report.
  We strongly encourage investors to carefully read the factors described elsewhere in this report in the section entitled &quot;Risk
  Factors&quot; for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking
  statements. We assume no responsibility to update the forward-looking statements contained in this quarterly report on Form 10-Q.
  The following should also be read in conjunction with the unaudited Financial Statements and notes thereto that appear elsewhere
  in this report.</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Company Overview</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">As
  a result of the Company not receiving the working capital promised by certain third parties, development of the two business segments
  described below has been slow, and generated no revenues since its inception on October 15, 2013. In August 2017, changing our
  name and pursuing the various biomedical opportunities which had been presented to us, one of which, the patents and other rights
  owned by GandTex seemed very attractive and we elected to acquire the patents purportedly owned by GandTex and develop what is
  now termed the &ldquo;NuLife Process&rdquo; or NuLife Technique&rdquo;. As a result of operating difficulties relating primarily
  to the hurricanes and related severe weather in southern Florida, the home of our Animal Trials, and the discovery that certain
  critical information related to the actual surgical process has been withheld by the inventor of the NuLife Process, we suspended
  the organ transplantation activities in October 2017. In connection with the return of the Exclusive License to Duplitrans and
  the return of and the patent rights acquired from GandTex pursuant to individual Settlement and Release Agreements with Duplitrans
  and GandTex (the &ldquo;Settlement Agreements).</FONT></P>
  
  <P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">While
  the organ transplantation activities were suspended we began investigating other applications of the NuLife Process, in particular
  the Wound Care Technique. </FONT>To date, the Company&rsquo;s participation in the proposed Wound Care activities are still in
  the investigation stage, without significant expenditures by the Company due to our efforts to maintain adequate funding for our
  corporate operations. Further, the commercial relationship between the NuGenesis and Duplitrans has not yet been established in
  an adequate definitive joint venture agreement, but only through the MOU during this exploratory stage of the business. Neither
  the Company or NuGenesis currently have the necessary funding to resume the development of the Wound Care Technique, and the reduction
  of the MOU to a definitive agreement is contingent upon either the Company or NuGenesis obtaining the funding necessary to carry
  the proposed development through to completion</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Online marketplace
  and community</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company's initially-defined
  business strategy is to acquire and/or develop and market software and services that will significantly enhance the performance
  and functionality of the Internet services used by individuals and by small to medium sized businesses. However, .it appears that
  the Website will not be competitive in the &ldquo;service&rdquo; sector of the Internet space without certain modifications, ,
  but could have other applications which we may consider pursuing depending upon the results of the current Animal Trials, our investigation
  of the Wound Care Process and the potential opportunities in the oncology data management space. Since the acquisition of the organ
  transplant technology, we narrowed the focus of our platform to the healthcare industry and have, for now, suspended the modification
  of the Website.</P>
  
  
  <!-- Field: Page; Sequence: 21 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">However,
  with the <FONT STYLE="background-color: white">Settlement Agreements</FONT> and unwinding of the Asset Acquisition, and the shift
  in our structure and direction in the healthcare industry to attempt to become involved with NuGenesis in the development of the
  Wound Care Technique, as funding becomes available we intend to either (a) pursue the joint venture envisioned by the MOU with
  NuGenesis in the development of the Wound Care Technique, or (b) refocus on our Website and (i) modifying our online marketplace
  and community to focus on healthcare professionals and those in need of individual at-home and post-operative care, together with
  Hospitals and physicians who need part time or additional personnel due for expansion, or (ii) simply updating the Website as www.anytimeJobs.com.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Critical Accounting Policies</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The preparation
  of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States
  of America requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses
  and related disclosures of contingent assets and liabilities in the financial statements and accompanying notes. The SEC has defined
  a company's critical accounting policies as the ones that are most important to the portrayal of the company's financial condition
  and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result
  of the need to make estimates of matters that are inherently uncertain. We believe that our estimates and assumptions are reasonable
  under the circumstances; however, actual results may vary from these estimates and assumptions. We have identified in Note 2 -
  &quot;Summary of Accounting Policies&quot; to the Financial Statements contained in this Quarterly Report certain critical accounting
  policies that affect the more significant judgments and estimates used in the preparation of the financial statements<B>.</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Going Concern</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Our auditor has
  issued a &quot;going concern&quot; qualification as part of its opinion in the Audit Report for the fiscal year ended September
  30, 2017, and our financial statements as of and for the year then ended include a &quot;going concern&quot; footnote (See Footnote
  3 &ndash; Going Concern) disclosing that our ability to continue as a going concern is contingent on us to be able to raise working
  capital to generate revenue by completing and launching our online marketplace and community portal and implementing the new business
  strategy of developing the NuLife Process.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Results of Operation</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Three Months Ended December 31,
  2017 and 2016</I></B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Revenue.</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Revenue was $0
  for the three months ended December 31, 2017 and 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cost of Sales.</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Cost of sales
  was $0 for the three months ended December 31, 2017 and 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Operating Expenses.</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Operating expenses
  were $811,769 and $402,260 for the three months ended December 31, 2017 and 2016, respectively. Operating expenses consist of general
  and administrative expenses and related party compensation. During the three months ended December 31, 2017 and 2016 general and
  administrative expenses were $768,775 and $98,856, respectively. During the three months ended December 31, 2017 and 2016, the
  Company recorded $640,000 and $-0- of stock-based compensation to non-related parties. During the three months ended December 31,
  2017 and 2016 related party compensation was $42,994 and $303,404, respectively. Related party compensation included $186,904 of
  stock-based compensation during the three months ended December 31, 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>
  
  
  <!-- Field: Page; Sequence: 22 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Interest Expense.</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Interest expense
  was $201,254 and $36,479 for the three months ended December 31, 2017 and 2016, respectively, which related to interest accrued
  on borrowings, which were greater at December 31, 2017 as a result of newly issued debt. Included in interest expense for the three
  months ended December 31, 2017 and 2016, was also $91,617 and $14,392, respectively, of non-cash interest expense related to the
  amortization of the debt discount and beneficial conversion feature.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Interest Income.</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Interest income
  was $-0- and $504 for the three months ended December 31, 2017 and 2016, respectively, which related to interest due on notes receivable
  and interest earned in bank accounts, which were greater in the three months ended December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Forgiveness of Accounts Payable.</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">During the three
  months ended December 31, 2017, a vendor cancelled the amount the Company owed. Accordingly, the Company recorded a forgiveness
  of debt in the amount of $73,644.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Gain(Loss) on derivative.</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The Company recorded
  a net gain on derivative in the amount of $61,221 in the three months ended December 31, 2017 compared to a loss on derivative
  of $14,319 during the three months ended December 31, 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The following
  is a summary of the Company's cash flows provided by (used in) operating, investing, and financing activities for the three months
  ended December 31, 2017 and 2016:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: justify; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2016</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="width: 60%; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Activities</FONT></TD>
      <TD STYLE="width: 7%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 11%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(92,493</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
      <TD STYLE="width: 7%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 11%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(182,568</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing Activities</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&nbsp;&nbsp;</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing Activities</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,410</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">685,000</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Effect on Cash</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(44,083)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">502,432</FONT></TD>
      <TD>&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Since acquiring
  the business plan and Website, during our fiscal year ended September 30, 2016, most of our resources and work was devoted to the
  development of the Website segment of our business. However, this has been suspended for the time being due to certain modifications
  needed to eliminate the risk of cyber-attacks. When those procedures are completed, which we believe will occur over several months
  following the receipt of adequate financing, we may resume work on our Website as well further internal development of software
  for which we have developed our initial framework of and completed some coding. We believe that the work needed to initiate and
  complete the software development for our online marketplace and community portal, attract developers, and initiate our marketing
  plans, including the development of a saleable product suite, may be in excess of $100,000 if outside contractors and experts are
  used. If we are able to secure funding to outsource these procedures, of which there are no assurances, we will then commence the
  launch of our intended services and software products to the public. If we are able to use internal resources only (primarily consisting
  of the services of our president and chief financial officer), the process will take much longer and our initial launch may be
  limited to a much smaller target market. If we are unable to raise any funds from third party sources, the development costs would
  have to be funded by current shareholders, management or by third-parties through the issuance of Convertible or Demand Promissory
  Notes. While we have previously engaged the services of an established software development firm which we used on an as &quot;needed
  basis&quot;, their involvement is limited by our ability to raise financing. Our goal would be to have software products available,
  services available, multiple sales channels and a comprehensive corporate website up and running within one year after receipt
  of adequate financing, but there is no way of estimating what the likelihood of achieving that goal would be.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 23 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">If a market for
  our shares ever develops, of which there can be no assurances, we may continue to use restricted shares of our common stock or
  stock options to compensate employees/consultants and independent contractors wherever possible. We cannot predict the likelihood
  or source of raising capital or funds that may be needed to complete the development of our business plan and its stages as outlined
  above.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As a public company,
  we will incur ongoing expenses associated with professional fees for accounting, legal and a host of other expenses including annual
  reports and proxy statements, if required. We estimate that these costs will range up to $50,000 per year over the next few years
  and may be significantly higher if our business volume and transactional activity increases, and we would not be subject to the
  requirements of Section 404 of the Sarbanes-Oxley Act of 2002 for an opinion on our system on internal controls by our independent
  audit firm unless and until we exceed $75 million in market capitalization. These obligations may reduce our ability and resources
  to expand our business plan and activities. We hope to be able to use our status as a public company to increase our ability to
  use noncash means of settling outstanding obligations (i.e. issuance of restricted shares of our common stock) and compensate independent
  contractors who provide professional services to us, although there can be no assurances that we will be successful in any of these
  efforts. We will also reduce compensation levels paid to management (if we attract or retain outside personnel to perform this
  function) if there is insufficient cash generated from operations to satisfy these costs.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">We are presently
  seeking equity and debt financing for both segments of our business. However, these actions, if successful, could result in dilution
  of the ownership interests of existing shareholders and further dilute common stock book value, and such dilution may be material.
  The Company may offer shares of its common stock to settle a portion of the professional fees incurred in connection with its registration
  statement. No negotiations have taken place with any professional and no assurances can be made as to the likelihood that any professional
  will accept shares in settlement of obligations due them.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of December
  31, 2017, we owed $610,410 in accounts payable, accrued expenses and to related parties, a substantial portion of which are past
  due. The only agreements, written or oral, with any vendors or other providers for payment of services or expenses are with respect
  to (i) contracted investor relation services, and (ii) compensation to the Company's President, our Chief Executive Officer and
  our Chief Financial Officer, one of whom is a director. There are no other significant liabilities at December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of December
  31, 2017, the Company had one note payable issued and outstanding to a third-party lender with a total principle of $25,000 and
  accrued interest of $15,912. The note was due on June 30, 2015, has an interest rate of 12%. This note is in default and remains
  unpaid at December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31,
  2017, the Company had three notes payable issued and outstanding with a former director with a total principle of $74,500 and accrued
  interest of $14,366. The three notes, in the amount of $47,000, $15,000 and $12,500, were issued on January 14, 2016. February
  10, 2016 and February 29, 2016, respectively. The three notes are due on the earlier of one week after the closing of a certain
  contemplated farm property acquisition or July 31, 2016, and have an interest rate of 10%. The former director for all three notes
  is East West Secured Developments, LLC, an Arizona Limited Liability Company (&ldquo;EWSD&rdquo;) of which Mr. Brian Loiselle,
  the EWSD Managing Member, was also a former director of the Company. On June 30, 2016, the Company entered into Amendment #1 to
  these three notes to extend the due date to one week after the closing of a certain contemplated farm property acquisition or October
  31, 2016. The three notes have been reclassified to non-related party debt. See NOTE 6 above.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 28,
  2017, the Company entered into a note payable in the aggregate principal amount of $106,410. The Note matures on March 31, 2018,
  and bears interest at the rate of 12% per annum. As of December 31, 2017, the note balance and accrued interest is $106,410 and
  $105, respectively. This note remains unpaid at December 31, 2017</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of December
  31, 2017, the Company had five convertible notes payable issued and outstanding with a total principle of $222,500 and accrued
  interest of $5,437. The notes are due December 31, 2017 through October 13, 2020 and have interest rates of 5% to 12%. The notes
  remain unpaid as of December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Off-Balance Sheet Arrangements</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">We have not entered
  into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
  condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
  resources and would be considered material to investors.</P>
  
  <!-- Field: Page; Sequence: 24 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Contractual Obligations </B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As a &ldquo;smaller reporting company&rdquo;
  as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_004"></A>Item 3. Quantitative and Qualitative
  Disclosures about Market Risks</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Not applicable because we are a smaller
  reporting company.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_005"></A>Item 4. Controls and Procedures</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Evaluation of Disclosure Controls
  and Procedures&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Pursuant to Rule 13a-15(b) under the
  Securities Exchange Act of 1934 (&ldquo;Exchange Act&rdquo;), the Company carried out an evaluation, with the participation of
  the Company&rsquo;s management, including the Company&rsquo;s President (the &ldquo;President&rdquo;) and principal Financial Officer,
  of the effectiveness of the Company&rsquo;s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange
  Act) as of the end of the period covered by this report. Based upon that evaluation, the Company&rsquo;s President and principal
  financial officer concluded that the Company&rsquo;s disclosure controls and procedures were not effective to ensure that information
  required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed,
  summarized and reported, within the time periods specified in the SEC&rsquo;s rules and forms, and that such information is accumulated
  and communicated to the Company&rsquo;s management, including the Company&rsquo;s President and principal financial officer, as
  appropriate, to allow timely decisions regarding required disclosure as a result of continuing material weaknesses (such as the
  absence of an audit committee and absence of qualified independent directors) in its internal control over financial reporting.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Changes in Internal Controls Over
  Financial Reporting</I></B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">There have been no changes in the Company's
  internal control over financial reporting during the latest fiscal quarter that have materially affected, or are reasonably likely
  to materially affect, the Company's internal control over financial reporting.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 25 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_006"></A>PART II - OTHER INFORMATION</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_007"></A>Item 1. Legal Proceedings.</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company owes
  on promissory notes that have an aggregate principal amount of $74,500 and are simple promissory notes with 10% annual interest
  to EWSD. The notes are in default, but there is not a default interest provided in the notes. Therefore, the notes continue to
  accrue interest at 10% per annum until paid or collected. Mr. Loiselle is demanding 18% per month interest for the past four months
  to the present. The Company has disputed this interest that is not detailed on the notes. Furthermore, Mr. Loiselle is claiming
  unpaid compensation of $10,000 per month for services without an agreement with the Company. These charges are also being disputed
  by the Company. These disputes represent a material risk, and may be litigated in the future other than the aforementioned, the
  Company currently has no other litigation pending, threatened or contemplated, or unsatisfied judgments.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time,
  we are also a party to certain legal proceedings incidental to the normal course of our business including the enforcement of our
  rights under contracts with contractors and suppliers. While the outcome of these legal proceedings cannot at this time be predicted
  with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of
  operations.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_008"></A>Item 1A. Risk Factors</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable because
  we are a smaller reporting company.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_009"></A>Item 2. Unregistered Sales of Equity
  Securities and Use of Proceeds</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In October 2013,
  following the Company's incorporation on October 15, 2013, the Company issued 7,250,00 shares of our common, now 21,750,000 shares
  following the 3:1 forward stock split, stock to its founder, Derek Cahill, as consideration for the purchase of a business plan
  along with a website. The acquisition of the business plan and website was valued at $72,500.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 29, 2013,
  the Company completed a private placement whereby it issued 5,400,000 shares of common stock to accredited investors at $0.003
  per share for total gross proceeds of $18,000.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 16, 2014,
  the Company completed a public offering whereby it issued 1,735,800 shares of common stock at $0.042 per share for total gross
  proceeds of $72,325. The Company's Registration Statement on Form S-1 was declared effective March 6, 2014.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 7, 2015,
  the Company granted 100,000 shares of restricted common stock to its chief operating officer. On the date of the grant, the shares
  were valued at $.61 per share which was the unadjusted closing share price on that date for a fair value of $61,000. The shares
  vest over a six-month period, with the vested shares recorded on the accompanying balance sheet under equity - shares to be issued.
  The subject 100,000 shares of common stock will be issued in a subsequent period.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company amended
  and restated that certain outstanding promissory note of the Company, dated July 3, 2015, and in the principal amount of $50,025
  (the &quot;Default Note&quot;). The replacement convertible promissory note (the &ldquo;Exchange Note&rdquo;) matures on December
  31, 2017 (the &ldquo;Maturity Date&rdquo;), and bears interest at the rate of 8% per annum, and the principal and interest due
  thereunder may be prepaid at any time. The Exchange Note, together with all interest as accrued, is convertible into shares of
  the Company&rsquo;s common stock at $0.11, which amount represents the average trailing average high closing Ask price of the Company&rsquo;s
  common stock as of the date of issuance of the Exchange Note.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 2,
  2016, the Company entered into those certain Note Purchase Agreements (collectively, the &ldquo;Purchase Agreements&rdquo;) in
  connection with the issuance of certain convertible promissory notes (collectively, the &ldquo;Purchase Notes&rdquo;) in the aggregate
  principal amount of $50,000. All of the Purchase Notes mature thirty-six months from the date of issuance (the &ldquo;Maturity
  Date&rdquo;), and bear interest at the rate of 10% per annum. Each of the Purchase Notes may be prepaid until the Maturity Date
  at 110% of the principal and interest amount outstanding. The Purchase Notes, together with all interest as accrued, are each convertible
  into shares of the Company&rsquo;s common stock at 50% of the trailing average highest closing bid price of the Company&rsquo;s
  common stock on the date of conversion. The Purchase Agreements and the Purchase Notes contain representations, warranties, conditions,
  restrictions, and covenants of the Company that are customary in such transactions with smaller companies.</P>
  
  <!-- Field: Page; Sequence: 26 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Also, on September
  2, 2016, the Company amended and restated the Default Note. The Exchange Note matures on December 31, 2017, and bears interest
  at the rate of 8% per annum, and the principal and interest due thereunder may be prepaid at any time. The Exchange Note, together
  with all interest as accrued, is convertible into shares of the Company&rsquo;s common stock at $0.11, which amount represents
  the average trailing average high closing Ask price of the Company&rsquo;s common stock as of the date of issuance of the Exchange
  Note.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&emsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Purchase Notes
  may be accelerated by the holders thereof in the event of default. In addition, the amounts due and payable under the Purchase
  Notes (and, consequently, the number of shares of common stock convertible thereunto) may be increased to 150% of the principal
  and interest amounts of the Purchase Notes. The Purchase Notes are a direct financial obligation of the Company and are considered
  a current liability of the Company for accounting purposes.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We relied upon Section
  4(2) of the Securities Act of 1933, as amended for the above private placement issuances. We believed that Section 4(2) was available
  because:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;None of
  these issuances involved underwriters, underwriting discounts or commissions</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;We placed
  restrictive legends on all certificates issued</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;No sales
  were made by general solicitation or advertising</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;Sales were
  made only to accredited investors</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with
  the above transactions, we provided the following to all investors:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;Access to
  all our books and records</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;Access to
  all material contracts and documents relating to our operation</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;The opportunity
  to obtain any additional information, to the extent we possessed such information, necessary to verify the accuracy of the information
  to which the investors were given access.</P>
  
  
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Pursuant
  to the terms of the Asset Purchase Agreement with GandTex, on December 30, 2016 the Board approved the issuance of 10,000,000 shares
  of the Company&rsquo;s Series B Convertible Preferred Stock to GandTex. The shares were released to GandTex concurrent with the
  closing on January 29, 2017. </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
  January 20 , 2017, the Company entered into a Debt Conversion Agreement (the &ldquo;Conversion Agreement&rdquo;) in respect of
  $13,750 of the accruing monthly fees due to MZHCI, LLC(&ldquo;MZ&rdquo;) by the Company pursuant to the Investor Relations Consulting
  Agreement between MZ and the Company dated April 1, 2015 (the &ldquo;Debt&rdquo;) together with a release by MZ in favor of the
  Company for any claims for reimbursement of any and all due diligence expenses, investigative costs or any other type of fees or
  costs incurred by MZ related to the recent purchase by the Company of the GandTex Assets. Pursuant to the terms of the Conversion
  Agreement, the Company issued to MZ an aggregate of 55,000 shares of restricted Series A Convertible Preferred Stock.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
  February 28, 2017 the Company entered into an Advisory Agreement with Global Business Strategies Inc.(&ldquo;Global&ldquo;), a
  Company owned by the Company&rsquo;s President Fred G. Luke (&ldquo;the &ldquo;Global Agreement&rdquo;), pursuant to which the
  Company retained Global to provide management advice and corporate development strategies, and to make Mr. Luke available to serve
  as the Company&rsquo;s President, for an aggregate of $8,500 per month and, subject to the condition that Global effected filing
  of the Company&rsquo;s its Quarterly Report for the period ending December 31, 2016 on Form 10-Q on a timely basis, Global received
  an aggregate of 55,000 shares of restricted Series A Convertible Preferred Stock.</P>
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
  June 26, 2017, the Company entered into a Securities Purchase Agreement (&ldquo;June SPA&rdquo;) in connection with the issuance
  of a convertible promissory note (&ldquo;June Note&rdquo;) in the aggregate principal amount of $78,000. The June Note matures
  on June 30, 2018 (the &ldquo;Maturity Date&rdquo;), and bears interest at the rate of 12% per annum. After 180 days, the June Note
  may not be prepaid. Any amount of principal or interest on the June Note which is not paid when due shall bear interest at the
  rate of twenty two percent (22%) per annum from the due date. The June Note, together with all interest as accrued, is convertible
  into shares of the Company&rsquo;s common stock at a 35% discount to</P>
  
  
  <!-- Field: Page; Sequence: 27 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">the lowest
  trading price in the 10-day period ending on the latest complete Trading Day prior to the Conversion Date. The June SPA and the
  June Note contain representations, warranties, conditions, restrictions, and covenants of the Company that are customary in such
  transactions with smaller companies.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 14, 2017,
  the Company entered into a Securities Purchase Agreement (&ldquo;SAP&rdquo;) in connection with the issuance of a convertible promissory
  note (the &ldquo;Kingdom Note&rdquo;) in the aggregate principal amount of $65,000. The Note matures on November 14, 2017 (the
  &ldquo;Maturity Date&rdquo;), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued,
  is convertible into shares of the Company&rsquo;s common stock at $0.11 per share. Due to the beneficial conversion feature of
  this note, the Company recorded $65,000 of debt discount as a contra liability and amortized $31,056 of the discount during the
  three months ended December 31, 2017. As of December 31, 2017, the note balance and accrued interest is $65,000 and $1,995, respectively.
  This note is in default and remains unpaid at December 31, 2017, however, the Company and the Payee entered into a Debt Conversion
  Agreement in February, 2018 pursuant to which the Payee received shares of the Company&rsquo;s Series A Convertible Preferred Stock
  in exchange for the full release of any and all obligations related to the Kingdom Note. Refer to NOTE 13. SUBSEQUENT EVENTS.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 23, 2017,
  the Company entered into a Securities Purchase Agreement (&ldquo;SAP&rdquo;) in connection with the issuance of a convertible promissory
  note (the &ldquo;Hayden Note&rdquo;) in the aggregate principal amount of $50,000. The Note matures on August 23, 2020 (the &ldquo;Maturity
  Date&rdquo;), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued, is convertible into
  shares of the Company&rsquo;s common stock at $0.11 per share. Due to the beneficial conversion feature of this note, the Company
  recorded $50,000 of debt discount as a contra liability and amortized $4,197 of the discount during the three months ended December
  31, 2017. As of December 31, 2017, the note balance and accrued interest is $50,000 and $1,424, respectively. This note remains
  unpaid at December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 12,
  2017, the Company entered into a Securities Purchase Agreement (&ldquo;SAP&rdquo;) in connection with the issuance of a convertible
  promissory note (the &ldquo;First Fire Note&rdquo;) in the aggregate principal amount of $82,500. The Note matures on September
  12, 2018 (the &ldquo;Maturity Date&rdquo;), and bears interest at the rate of 5% per annum. The Note, together with all interest
  as accrued, is convertible into shares of the Company&rsquo;s common stock at a 35% discount to the lowest trading price in the
  21-day period ending on the latest complete Trading Day prior to the Conversion Date. As of December 31, 2017, the note balance
  and accrued interest is $82,500 and $1,243. This note remains unpaid at December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 13, 2017,
  the Company entered into a Securities Purchase Agreement (&ldquo;SAP&rdquo;) in connection with the issuance of a convertible promissory
  note (the &ldquo;Escala Note&rdquo;) in the aggregate principal amount of $20,000. The Note matures on October 13, 2020 (the &ldquo;Maturity
  Date&rdquo;), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued, is convertible into
  shares of the Company&rsquo;s common stock at $0.30 per share. Due to the beneficial conversion feature of this note, the Company
  recorded $12,667 of debt discount as a contra liability and amortized $913 of the discount during the three months ended December
  31, 2017. As of December 31, 2017, the note balance and accrued interest is $20,000 and $346, respectively. This note remains unpaid
  at December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 28,
  2017, the Company entered into a note payable in the aggregate principal amount of $106,410. The Note matures on March 31, 2018,
  and bears interest at the rate of 12% per annum. As of December 31, 2017, the note balance and accrued interest is $106,410 and
  $105, respectively. This note remains unpaid at December 31, 2017</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">On December 29,
  2017, the Company issued 2,000,000 to Duplitrans and the legal counsel of Duplitrans in regards to the agreement with GandTex.
  On the date of the settlement, October 24, 2017, the shares had a fair market value of $640,000. Accordingly, the Company recorded
  $640,000 of stock based compensation during the three months ended December 31, 2017. All of the Company&rsquo;s 10,000,000 Series
  B Convertible Preferred Stock, previously issued to GandTex, were cancelled during the quarter ended December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of December
  31, 2017, the Company had five convertible notes payable issued and outstanding with a total principle of $222,500 and accrued
  interest of $5,437. The notes are due December 31, 2017 through October 13, 2020 and have interest rates of 5% to 12%. The notes
  remain unpaid as of December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>
  
  
  <!-- Field: Page; Sequence: 28 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_010"></A><B>Item 3. Defaults Upon Senior Securities.</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">None</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_011"></A>Item 4. Mine Safety Disclosures</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Not Applicable.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_012"></A>Item 5. Other Information.</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 29 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_013"></A><B>Item 6. Exhibits.</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 90%; border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<A HREF="ex311_302certification.htm">ertification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A>.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="line-height: 115%">31.2</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><A HREF="ex312_302certification.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A>.</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex321_906certification.htm">Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A>.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="line-height: 115%">32.2</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><A HREF="ex322_906certification.htm">Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A>.</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  <HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_014"></A><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the
  Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
  duly authorized.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NuLife Sciences, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 62%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
      February 23, 2018</FONT></TD>
      <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
      <TD STYLE="width: 35%; border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/&nbsp; Fred Luke</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fred Luke</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer and Principal Executive Officer)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 30; Options: Last -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "10-Q", "sequence": "1", "filename": "f10q_nulf12312017.htm", "description": "FORM 10-Q", "secsgml_size_bytes": 341603}]
metadata_filer: {"company-data": {"conformed-name": "NuLife Sciences, Inc.", "cik": "0001592603", "assigned-sic": "2834", "irs-number": "463876675", "state-of-incorporation": "NV", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "10-Q", "act": "34", "file-number": "000-55805", "film-number": "18637273"}, "business-address": {"street1": "2618 SAN MIGUEL", "street2": "SUITE 203", "city": "SAN CLEMENTE", "state": "CA", "zip": "92660", "phone": "949-973-0684"}, "mail-address": {"street1": "2618 SAN MIGUEL", "street2": "SUITE 203", "city": "SAN CLEMENTE", "state": "CA", "zip": "92660"}, "former-company": {"former-conformed-name": "SmooFi, Inc.", "date-changed": "20131121"}}
text: UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM 10-Q
  (Mark One)
  ☒
  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
  For the quarterly period ended December 31, 2017
  ☐
  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
  For the transition period from ______to______
  Commission File Number:
  000-54163
  NuLife Sciences, Inc.
  (Exact name of registrant as specified in its Charter)
  Nevada
  46-3876675
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employee Identification No.)
  2618 San Miguel, Suite 203
  Newport Beach, CA
  92660
  (Address of principal executive office)
  (Zip Code)
  (949) 973-0684
  (Registrant's telephone number,
  including area code)
  Not Applicable
  (Former Name, former address
  and former fiscal year, if changed since last report)
  Indicate
  by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
  Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and
  (2) has been subject to such filing requirements for the past 90 days.
  Yes
  ☒
  No
  ☐
  Indicate
  by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
  Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
  preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes
  ☒
  No
  ☐
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
  of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule
  12b-2 of the Exchange Act:
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer (Do not check if smaller reporting company)
  ☐
  Smaller reporting company
  ☒
  Table of Contents
  Indicate
  by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes
  ☐
  No
  ☒
  Indicate the number of shares outstanding
  of each of the issuer's classes of common stock as of the latest practicable date: As of February 20, 2017, there were 40,504,391
  shares of $0.001 par value common stock, issued and outstanding.
  1
  Table of Contents
  PART I:
  FINANCIAL INFORMATION
  Item 1:
  Financial Statements
  3
  Item 2:
  Management's Discussion and Analysis of Financial Condition and Results of Operation
  2
  0
  Item 3:
  Quantitative and Qualitative Disclosures about Market Risk
  24
  Item 4:
  Controls and Procedures
  2
  4
  PART II:
  OTHER INFORMATION
  Item 1:
  Legal Proceedings
  25
  Item 1A:
  Risk Factors
  25
  Item 2:
  Unregistered Sales of Equity Securities and Use of Proceeds
  2
  5
  Item 3:
  Defaults Upon Senior Securities
  28
  Item 4:
  Mine Safety Disclosures
  28
  Item 5:
  Other Information
  28
  Item 6:
  Exhibits
  29
  SIGNATURES
  29
  2
  Table of Contents
  PART I - FINANCIAL INFORMATION
  ITEM 1.  FINANCIAL STATEMENTS
  NuLife Sciences, Inc.
  (fka "SmooFi, Inc.")
  Condensed Consolidated
  Balance Sheets
  December 31,
  2017
  (Unaudited)
  September 30, 2017
  ASSETS
  CURRENT ASSETS:
  Cash
  $
  40
  $
  44,123
  Prepaid expenses
  —
  5,000
  Advances receivable
  —
  1,090
  Total Current Assets
  40
  50,213
  Security deposit
  4,871
  4,871
  TOTAL ASSETS
  $
  4,911
  $
  55,084
  LIABILITIES AND STOCKHOLDERS' DEFICIT
  CURRENT LIABILITIES:
  Accrued expenses
  $
  610,410
  $
  633,689
  Due to related parties
  135,730
  84,500
  Accrued interest
  35,821
  36,508
  Notes payable
  205,910
  99,500
  Convertible note, current portion, net
  92,380
  58,432
  TOTAL CURRENT LIABILITIES
  1,080,251
  912,629
  Convertible notes, net
  14,177
  23,027
  Derivative liability
  102,559
  231,733
  TOTAL LONG TERM LIABILITIES
  116,736
  254,760
  TOTAL LIABILITIES
  1,196,987
  1,167,389
  STOCKHOLDERS' DEFICIT:
  Preferred stock Series A, $0.001 par value; 15,000,000 shares authorized; 117,500 and 117,500 issued or outstanding, respectively
  118
  118
  Preferred stock Series B, $0.001 par value; 10,000,000 shares authorized; nil and 10,000,000 issued or outstanding, respectively
  —
  10,000
  Common stock, $0.001 par value; 475,000,000 shares authorized; 40,504,391 and 37,797,238 shares issued and outstanding, respectively
  40,504
  37,797
  Additional paid in capital
  6,251,065
  5,445,385
  Accumulated deficit
  (7,483,763
  )
  (6,605,605
  )
  TOTAL STOCKHOLDERS' DEFICIT
  (1,192,076
  )
  (1,112,305
  )
  TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
  $
  4,911
  $
  55,084
  The accompanying notes are
  an integral part of these financial statements.
  3
  Table of Contents
  NuLife Sciences, Inc.
  (fka "SmooFi, Inc.")
  Condensed Consolidated
  Statements of Operations
  For the Three Months Ended
  December 31, 2017 and 2016
  (Unaudited)
  2017
  2016
  Revenue
  $
  —
  $
  —
  Cost of sales
  —
  —
  Gross Profit
  —
  —
  Operating expense:
  General and administrative expenses
  (768,775
  )
  (98,856
  )
  Related party compensation
  (42,994
  )
  (303,404
  )
  Total operating expense
  (811,769
  )
  (402,260
  )
  Loss from operations
  (811,769
  )
  (402,260
  )
  Interest expense
  (201,254
  )
  (36,479
  )
  Interest income
  —
  504
  Forgiveness of accounts payable
  73,644
  —
  Gain (loss) on change in fair value of derivative and derivative expense
  61,221
  (14,319
  )
  Loss before provision for income tax
  (878,158
  )
  (452,554
  )
  Provision for income taxes
  —
  —
  Net loss
  $
  (878,158
  )
  $
  (452,554
  )
  Basic and diluted net loss per share
  $
  (0.02
  )
  $
  (0.01
  )
  Weighted average common shares outstanding – basic and diluted
  38,209,901
  31,085,800
  The accompanying notes are
  an integral part of these financial statements.
  4
  Table of Contents
  NuLife Sciences, Inc.
  (fka "SmooFi, Inc.")
  Condensed Consolidated Statement of
  Cash Flows
  For the Three Months Ended
  December 31, 2017 and 2016
  (Unaudited)
  2017
  2016
  CASH FLOW FROM OPERATING ACTIVITIES:
  Net loss
  $
  (878,158
  )
  $
  (452,554
  )
  Adjustments to reconcile net loss to net cash used in operating activities:
  Interest expense - amortization of debt discount
  170,765
  27,495
  (Gain) loss on change in fair value of derivative and derivative expense
  (61,221
  )
  14,319
  Stock-based compensation expense
  640,000
  186,904
  Forgiveness of accounts payable
  (73,644
  )
  —
  Note receivable
  —
  (504
  )
  Prepaid expenses
  5,000
  —
  Accounts payable and accrued expenses
  50,365
  35,656
  Due to related party
  52,320
  (2,867
  )
  Accrued interest payable
  2,080
  8,983
  Net Cash Used in Operating Activities
  (92,493
  )
  (182,568
  )
  CASH FLOW FROM FINANCING ACTIVITIES:
  Loan proceeds
  106,410
  685,000
  Proceeds from the issuance of convertible notes
  20,000
  —
  Payment of convertible notes
  (78,000
  )
  —
  Net Cash Provided by Financing Activities
  48,410
  685,000
  CHANGE IN CASH
  (44,083
  )
  502,432
  CASH AT BEGINNING OF PERIOD
  44,123
  1,086
  CASH AT END OF PERIOD
  $
  40
  $
  503,518
  SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
  Cash paid for:
  Interest
  $
  —
  $
  —
  Income taxes
  $
  —
  $
  —
  NON-CASH INVESTING AND FINANCING ACTIVITIES:
  Shares issued for convertible debt and interest
  $
  77,767
  $
  —
  Derivative liability written off due to payment of debt
  $
  67,953
  $
  —
  Initial value of beneficial conversion feature
  $
  12,667
  $
  —
  The accompanying notes are
  an integral part of these financial statements.
  5
  Table of Contents
  NULIFE SCIENCES, INC. AND SUBSIDIARIES
  NOTES TO CONDENSED CONSOLIDATED FINANCIAL
  STATEMENTS
  DECEMBER 31, 2017 and 2016
  (Unaudited)
  NOTE 1 - ORGANIZATION
  NuLife Sciences
  Inc., formerly SmooFi, Inc. (the "Company") was incorporated under the laws of the State of Nevada on October 15, 2013.
  The Company issued 7,250,000 shares of its common stock to our founder, Derek Cahill, as consideration for the purchase of a business
  plan along with a website.
  On April 21, 2015, the Board of Directors of the Company
  approved a three-for-one forward stock split of the Company's common stock (the "Forward Split"). Accordingly, shareholders
  owning shares of the Company's common stock received two additional shares of the Company for each share they owned, and Mr. Cahill's
  7,250,000 shares became 21,750,000 shares. Prior to the Forward Split the Company had 10,128,600 shares issued and outstanding
  and following the Forward Split the Company has 40,504,391 shares issued and outstanding.
  During
  our fiscal year ended September 30, 2017, the Company formed three subsidiaries in the state of Nevada: NuLife BioMed, Inc. ("NuLife
  BioMed"), NuLife Technologies, Inc. ("NuLife Technologies") and NuLife Medical Inc., ("NuLife Medical"),
  and one in the state of Wyoming: , NuLife Oncology LLC, a Wyoming Limited Liability Company ("NuLife Oncology"), the
  Managing Member of which is NuLife Technologies NuLife BioMed was the only active subsidiary during the first fiscal quarter ended
  December 31, 2017.
  On January 29,
  2017, the Company announced the completion of an Asset Purchase Agreement to acquire all of the assets (the "Asset Purchase")
  of GandTex LLC, a Texas Limited Liability Company ("GandTex"). GandTex is a biomedical company focused on advancing
  human organ transplant technology and medical research. The assets being transferred pursuant to the Asset Purchase consisted of
  certain proprietary patents for eliminating the need for an organ or tissue match, and the necessity for anti-rejection
  drugs, as well as management of, and historical data for, animal trials ("Animal Trials") conducted by GandTex(collectively,
  the "GandTex Assets"). Pursuant to the terms of the Asset Purchase, and upon achieving certain pro-forma goals, the
  Company agreed to provide additional funding for the Trials in the aggregate amount of $300,000. In exchange for the GandTex Assets,
  the Company issued to GandTex 10,000,000 shares of its Series B Convertible Preferred Stock. GandTex is owned and controlled by
  a single individual Managing Member who beneficially owns 70% of GandTex The Asset Purchase was amended by an Addendum to the Asset
  Purchase Agreement effective July 11, 2017, and subsequently restructured so as to perfect ownership of the GandTex Assets by way
  of the GandTex Restructuring Agreements effective July 27, 2017 between GandTex and Duplitrans Inc. ("Duplitrans"),
  and as to certain of the agreements, the Company. In late October 2017, the Company terminated the Asset Purchase and the GandTex
  Restructuring Agreements on October 24, 2017 in an unwinding of the Asset Purchase by way of a Settlement an Release Agreement
  dated October 24, 2017, involving the full return of the 10,000,000 shares of the Company's Series B Convertible Preferred
  Stock in exchange for a full release of any and all claims that Duplitrans or GandTex may have had against the Company, and the
  transfer of the patents contained within the GandTex Assets to GandTex, and the Exclusive License to Duplitrans, and we entered
  into a Memorandum of Understanding with NuGenesis, a new entity being formed by certain shareholders of Duplitrans, with the intent
  to continue the development of the Wound Care technique in concert with NuGenesis. On December 29, 2017, the Company issued 2,000,000
  common shares which 1,960,000 common shares were issued to Duplitrans and 40,000 common shares were issued to the legal counsel
  of Duplitrans in regards to the agreement with GandTex. On the date of the settlement, October 24, 2017, the shares had a fair
  market value of $640,000. Accordingly, the Company recorded $640,000 of stock based compensation during the three months ended
  December 31, 2017. Refer to NOTE 4 – Asset Purchase Agreement.
  NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
  Basis of Presentation
  The Company's
  financial statements are prepared using the accrual method of accounting. The Company elected a September 30 fiscal year-end. These
  financial statements present the consolidated financial statements of NuLife Sciences, Inc. and its two wholly owned subsidiaries,
  NuLife Biomed, NuLife Technologies, an NuLife Medical, along with NuLife Oncology, of which NuLife Technologies is the Managing
  Member, as of the Company's fiscal quarter ended December 31, 2017.
  6
  Table of Contents
  NuLife Technologies,
  Inc., NuLife Medical and NuLife Oncology were all inactive at December 31, 2017 and remain inactive as of the date of this report.
  The unaudited
  interim financial statements have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission.
  The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are,
  in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information
  and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally
  accepted in the United States of America have been omitted pursuant to such rules and regulations. These condensed consolidated
  financial statements should be read in conjunction with the audited financial statements and notes for the year ended September
  30, 2017 included in our Annual Report on Form 10-K. The results of the three-month period ended December 31, 2017 are not necessarily
  indicative of the results to be expected for the full year ending September 30, 2018.
  Cash Equivalents
  For purposes of
  the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with maturity of three months
  or less at the time of issuance to be cash equivalents. The Company does not have any cash equivalent as of December 31, 2017 and
  September 30, 2017.
  Stock-based Compensation
  The Company
  follows ASC 718-10,
  Stock Compensation
  , which addresses the accounting for transactions in which an entity
  exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains
  employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services
  received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited
  exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be
  recognized Nonemployee share-based payments are measured at fair value, based on either the fair value of the equity
  instrument issued or on the fair value of the services received. We determine the fair value of common stock grants based on
  the price of the common stock on the measurement date (which is the earlier of the date at which a commitment for performance
  by the counterparty to earn the equity instruments is reached, if there are sufficient disincentives to ensure performance,
  or the date at which the counterparty's performance is complete). We determine the fair value of preferred stock grants based
  on the price of the preferred stock as potentially converted into common stock and based on the underlying common stock on
  the measurement date (which is the earlier of the date at which a commitment for performance by the counterparty to earn the
  equity instruments is reached, if there are sufficient disincentives to ensure performance, or the date at which the
  counterparty's performance is complete).
  Use of Estimates and Assumptions
  Preparation of
  the financial statements in conformity with accounting principles generally accepted in the United States requires management to
  make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from
  those estimates. The Company has adopted the provisions of ASC 260.
  Management makes estimates that affect
  certain accounts including, deferred income tax, accrued expenses, fair value of equity instruments and reserves for any other
  commitments or contingencies. Any adjustments applied to estimates are recognized in the year in which such adjustments are determined.
  Loss per Share
  The basic loss
  per share is calculated by dividing the Company's net loss available to common shareholders by the weighted average number of common
  shares during the year. The diluted loss per share is calculated by dividing the Company's net loss available to common shareholders
  by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding
  is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. Diluted loss per share are the same
  as basic earnings loss per share due to the lack of dilutive items in the Company.
  7
  Table of Contents
  Fair Value Measurements and Disclosures
  Fair value estimates
  discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31,
  2017 and September 30, 2017. The respective carrying value of certain on-balance-sheet financial instruments, approximate their
  fair values. These financial instruments include cash, accounts receivable, accounts payable, accrued expenses and notes payable.
  Fair values were assumed to approximate carrying values for these financial instruments because they are short term in nature and
  their carrying amounts approximate fair values or they are receivable or payable on demand.
  The Company uses
  fair value measurements under the three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure
  for fair value measures. The three levels are defined as follows:
  •
  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  •
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  •
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.
  Fair Value Measurements
  Using Fair Value Hierarchy
  Level 1
  Level 2
  Level 3
  Convertible notes (net of discount) – December 31, 2017
  $
  —
  $
  —
  $
  106,557
  Convertible notes (net of discount) – September 30, 2017
  $
  —
  $
  —
  $
  81,459
  Derivative liability – December 31, 2017
  $
  —
  $
  —
  $
  102,559
  Derivative liability – September 30, 2017
  $
  —
  $
  —
  $
  231,733
  The following table
  provides a summary of the changes in fair value of the Company's Convertible Promissory Notes, which are both Level 3 liabilities
  as of December 31, 2017:
  Balance at September 30, 2017
  $
  81,459
  Issuance of notes
  20,000
  Accretion of debt discount
  91,617
  Debt discount on convertible notes due to beneficial conversion feature
  (12,667
  )
  Accretion of debt discount due to beneficial conversion feature
  79,148
  Payment of convertible debt
  (78,000
  )
  Conversion of principal into shares of common stock
  (75,000
  )
  Balance December 31, 2017
  $
  106,557
  The Company determined
  the value of its convertible notes using a market interest rate and the value of the derivative liability issued at the time of
  the transaction less the accretion. There is no active market for the debt and the value was based on the delayed payment terms
  in addition to other facts and circumstances at the end of December 31, 2017 and September 30, 2017.
  The Company determined
  the value of warrants issued to a consultant using the Black-Scholes Model. There is no active market for the warrants and the
  value was based on the warrant terms in addition to other facts and circumstances at the end of the Company's first quarter
  ended December 31, 2017 and its fiscal year ended September 30, 2017.
  Derivative Financial Instruments
  The Company evaluates
  our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
  For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at
  its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
  For stock-based financial instruments, the Company uses the Black-Scholes-Merton pricing model to value the derivative instruments.
  The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity,
  is evaluated
  8
  Table of Contents
  at the end of each reporting period.
  Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash
  settlement of the derivative instrument could be required within 12 months of the balance sheet date.
  The classification
  of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at
  the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value
  of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current
  or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet
  date.
  The Company estimates
  the fair value of these instruments using the Black-Scholes option pricing model and the intrinsic value if the convertible notes
  are due on demand.
  We have determined
  that certain convertible debt instruments outstanding as of the date of these financial statements include an exercise price "reset"
  adjustment that qualifies as derivative financial instruments under the provisions of ASC 815-40, Derivatives and Hedging - Contracts
  in an Entity's Own Stock ("ASC 815-40"). Certain of the convertible debentures have a variable exercise price,
  thus are convertible into an indeterminate number of shares for which we cannot determine if we have sufficient authorized shares
  to settle the transaction with. Accordingly, the embedded conversion option is a derivative liability and is marked to market through
  earnings at the end of each reporting period. Any change in fair value during the period recorded in earnings as "Other income
  (expense) - gain (loss) on change in derivative liabilities." Please refer to Note 8 below.
  Income Taxes
  Income taxes are
  provided in accordance with ASC 740,
  Income Taxes
  . A deferred tax asset or liability is recorded for all temporary
  differences between financial and tax reporting and net operating loss carry forwards. Deferred tax expense (benefit) results from
  the net change during the year of deferred tax assets and liabilities.
  Deferred tax assets
  are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of
  the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax
  laws and rates on the date of enactment.
  No provision was
  made for Federal or State income taxes.
  Advertising
  Advertising will
  be expensed in the period in which it is incurred. There have been no advertising expenses for the reporting periods presented.
  Intangible Assets
  Intangible assets
  with finite lives are amortized over their estimated useful life. The Company monitors conditions related to these assets to determine
  whether events and circumstances warrant a revision to the remaining amortization period. The Company tests its intangible assets
  with finite lives for potential impairment whenever management concludes events or changes in circumstances indicate that the carrying
  amount may not be recoverable. The original estimate of an asset's useful life and the impact of an event or circumstance on either
  an asset's useful life or carrying value involve significant judgment.
  Research and Development
  Research is planned
  search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing
  a new product or service (hereinafter "product") or a new process or technique (hereinafter "process")
  or in bringing about a significant improvement to an existing product or process. Development is the translation of research findings
  or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or
  process whether intended for sale or use. It includes the conceptual formulation, design, and testing of product alternatives,
  construction of prototypes, and operation of pilot plants. It does not include routine or periodic alterations to existing products,
  production lines, manufacturing processes, and other on-going operations even though those alterations may represent improvements
  and it does not include market research or market testing activities. Per ASC 730, the Company expenses research and development
  cost as incurred.
  9
  Table of Contents
  Recently Issued Accounting Pronouncement
  s
  In February 2016,
  the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840).
  ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves accounting for the lessor largely unchanged.
  The amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal
  years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing
  at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company
  is currently evaluating the impact of this new standard on its consolidated financial statements.
  In March 2016,
  the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-09, "Compensation
  - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"). The
  standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax
  impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods
  within those years, beginning after December 15, 2016, and early adoption is permitted. The Company has adopted this new standard.
  In January 2017,
  the FASB issued Accounting Standards Update No. 2017-01,
  Business Combinations (Topic 805): Clarifying the Definition of
  a Business
  (ASU 2017-01), which revises the definition of a business and provides new guidance in evaluating when a set
  of transferred assets and activities is a business. This guidance will be effective for the Company in the first fiscal quarter
  of 2018 on a prospective basis, and early adoption is permitted. The Company does not expect the standard to have a material impact
  on our consolidated financial statements.
  In July 2017,
  the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2017-11 ("ASU 2017-11")
  which changes the accounting for equity instruments that include a down round feature.  For public entities, this update is
  effective for fiscal years beginning after December 15, 2018, and interim periods within those years.  Early adoption is permitted.
   The Company does not anticipate the adoption of this amendment will have an impact on the consolidated financial statements and
  related disclosures as the Company does not have any related equity instruments.
  The Company reviewed
  all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC and
  they did not or are not believed by management to have a material impact on the Company's present or future financial statements.
  NOTE 3 – GOING CONCERN
  The accompanying
  consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the three
  months ended December 31, 2017, the Company had a net loss of $878,158. As of December 31, 2017, the Company had a working capital
  deficit of $1,080,211 and an accumulated deficit of $7,483,763. The Company does not have a source of revenue and does not anticipate
  having one in the near future. Without additional capital, the Company will not be able to remain in business within the next twelve
  months.
  These factors raise
  a substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do
  not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts
  and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.
  Management has plans
  to address the Company's financial situation as follows:
  In the near term,
  management plans to continue to focus on raising the funds necessary to implement the Company's business plan. Management
  will continue to seek out debt financing to obtain the capital required to meet the Company's financial obligations. There
  is no assurance, however, that lenders will advance capital to the Company or that the new business operations will be profitable.
  The Company's future plans is fully dependent upon the funding of NuGenesis sufficient to carry forward the research on the
  Wound Care Process, and upon the ability of Duplitrans to also obtain sufficient funding to continue with the development of the
  NuLife Process at the Company's existing facilities.
  10
  Table of Contents
  The possibility of failure in obtaining additional
  funding and the potential inability to achieve profitability raise doubts about the Company's ability to continue as a going
  concern.
  In the long term,
  management believes that the Company's projects and initiatives will be successful and will provide cash flow to the Company,
  which will be used to finance the Company's future growth. However, there can be no assurances that the Company's planned
  activities will be successful, or that the Company will ultimately attain profitability. The Company's long-term viability
  depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation
  of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to
  sustain its operations. Substantial doubt has not been alleviated from management's plan at this time.
  NOTE 4 – ASSET PURCHASE AGREEMENT
  Following
  the Closing of the Asset Purchase, in March 2017, we learned that Mr. James Gandy did not have proper authority to transfer the
  Exclusive License rights from Duplitrans to GandTex, after which we proposed a restructuring of the transaction, which was approved
  by the Duplitrans shareholders, so that we ended up with exclusive use and ownership of the intellectual property that was in dispute,
  but at the same time the Duplitrans shareholders were compensated for the license termination by way of an amendment to the conversion
  terms of the Series B Preferred Stock and a Royalty Agreement in favor of Duplitrans (the "GandTex Restructuring").
  Following
  our initial stage of the resumption of the Animal Trials conducted earlier in Ecuador by Duplitrans and GandTex, and the GandTex
  Restructuring, we learned that certain critical information concerning the organ transplantation process, thought to be contained
  in the GandTex Assets, was not contained in any of the Patents or License comprising the GandTex Assets, and was withheld by the
  inventor, Mr. Gandy during his review of our Protocol for the transplantation procedures (the "Omitted Transplantation Information").
  In October 2017, as described in our Form 8-K filed October 21, 2017 following the discovery of the Omitted Transplantation Information,
  we entered into a settlement agreements with Duplitrans and GandTex pursuant to which we reversed the Asset Acquisition and the
  GandTex Restructuring Agreements in their entirety, and GandTex and Duplitrans agreed to the full return of the 10,000,000 shares
  of our Series B Preferred Stock, the cancellation of the Royalty Agreement with Duplitrans/GandTex, and a full release by GandTex
  and Duplitrans from any and all claims that they may have believed they had against us (the "Release"). In consideration
  for the termination of the Asset Purchase Agreement and the GandTex Restructuring Agreements, the Release and the return of our
  Series B Preferred Stock, we issued 2,000,000 shares of our common Stock to Duplitrans and to Duplitrans legal counsel.
  In conjunction
  with Mr. Gandy's final disclosure of the Omitted Transplantation Information, but prior to the Release and unwinding of the
  Asset Purchase, we entered into a Memorandum of Understanding (the "MOU") with NuGenesis, an entity in formation organized
  by certain of the Duplitrans shareholders ("NuGenesis"), which we believed could enable us to continue to pursue the
  Animal Studies and a secondary application of the NuLife Process – known as the "Wound Care Technique".
  To
  date, the proposed Wound Care activities (the "Wound Care Technique") are still in the investigation stage, without
  significant expenditures by the Company due to our efforts to maintain adequate funding for our corporate operations. The commercial
  relationship between the NuGenesis and Duplitrans has not yet been established in an adequate definitive joint venture agreement,
  but only through the MOU during this exploratory stage of the business. Neither the Company or NuGenesis currently have the necessary
  funding to resume the development of the Wound Care Technique, and the reduction of the MOU to a definitive agreement is contingent
  upon either the Company or NuGenesis obtaining the funding necessary to carry the proposed development through to completion
  NOTE 5 - CONSULTING AGREEMENTS
  On April 1, 2015,
  the Company entered into a twelve-month consulting agreement with an investor relations firm. Per the agreement, the Company will
  pay the consultant a monthly fee of $8,500 on the first day of each month with the payment deferred until the Company closes financing
  in the amount of $3 million or greater. Additionally, the Company was required to issue the consultant 200,000 shares of common
  stock on October 1, 2015. The agreement was terminated on October 16, 2016. During the three months ended December 31, 2017 and
  2016, the Company recorded compensation expense in the amount of $-0- and $2,133 related to this agreement.
  11
  Table of Contents
  On
  February 28, 2017, but effective January 5, 2017, the Company entered into an Advisory Agreement with Global Business Strategies
  Inc. ("Global "), a company controlled Mr. Luke (the "Global Agreement"). Pursuant to the Global Agreement
  the Company retained Global to provide management advice, corporate development strategies, to
  assist in the general and
  administrative functions
  , and to make Mr. Luke available to serve as a Director or a member
  of the Company's management (the "Services" as defined in the Global Agreement).  In consideration for the
  Services the Company agreed to pay Global $8,500 per month, which included any and all fees for Mr. Luke continuing to serve as
  the Company's President and fees to others working for Global, and allowed for reimbursement of expenses up to $500 per month
  without prior written approval. The Company also agreed to pay Global an additional $1,500 per month if Mr. Luke was appointed
  to serve as a Director also incorporated you of the Company, and agreed to issue to Global
  55,000 shares of its Series A
  Convertible Preferred Stock. Mr. Luke has not been appointed a Director of the Company as of the date of this report. During the
  three months ended December 31, 2017 and 2016, the Company recorded compensation expense in the amount of $25,500 and $-0- related
  to this agreement.
  On June 10, 2017,
  the Company entered into a Master Service Agreement with an investment consultant to provide services to the Company for a period
  of six months. The agreement calls for a budget of $215,000 with an initial payment of $150,000. Additionally, the agreement called
  for the issuance of 250,000 cashless warrants exercisable for three years at a price of 110% of the closing price on June 10, 2017.
  The Company paid $65,000 of the initial payment on August 14, 2017, the remaining $85,000 of the initial payment and $65,000 of
  the balance of the agreement, for a total of $150,000 is included in accounts payable as of December 31, 2017 and September 30,
  2017. See Note 13– Subsequent Events.
  NOTE 6 – NOTES PAYABLE
  As of December
  31, 2017, the Company had a note payable issued and outstanding to a third-party lender with a total principle of $25,000 and accrued
  interest of $15,912. The note was due on June 30, 2015, has an interest rate of 12%. This note is in default and remains unpaid
  at December 31, 2017. The Company has been able in the past to arrange equity or debt financing sufficient to pay off its notes,
  not in dispute, but there cannot be any assurance that the Company will be able to continue to attract such financing in the future.
  As of December 31,
  2017, the Company had three notes payable issued and outstanding with a former director with a total principle of $74,500 and accrued
  interest of $14,366. The three notes, in the amount of $47,000, $15,000 and $12,500, were issued on January 14, 2016. February
  10, 2016 and February 29, 2016, respectively. The three notes are due on the earlier of one week after the closing of a certain
  contemplated farm property acquisition or July 31, 2016, and have an interest rate of 10%. The former director for all three notes
  is East West Secured Developments, LLC, an Arizona Limited Liability Company ("EWSD") of which Mr. Brian Loiselle,
  the EWSD Managing Member, was also a former director of the Company. On June 30, 2016, the Company entered into Amendment #1 (the
  "EWSD Amendment") to these three notes to extend the due date to one week after the closing of a certain contemplated
  farm property acquisition or October 31, 2016. The three notes have been reclassified to non-related party debt. Since the closing
  of the contemplated farm property never occurred, the Company has taken the position, pursuant to the language of the EWSD Amendments,
  that there is not legal date for repayment, and it intends to leave the subject notes on its Financial Statements until a mutual
  settlement agreement can be reached between Mr. Loiselle and the Company.
  On December 28,
  2017, the Company entered into a note payable in the aggregate principal amount of $106,410. The Note matures on March 31, 2018,
  and bears interest at the rate of 12% per annum. As of December 31, 2017, the note balance and accrued interest is $106,410 and
  $105, respectively. This note remains unpaid at December 31, 2017.
  12
  Table of Contents
  NOTE 7 – CONVERTIBLE NOTES
  Convertible notes consist of the following:
  December 31, 2017
  September 30,
  2017
  Convertible note payable, annual interest rate of 8%, convertible into common stock at $0.11 per share and due December 2019.
  $
  5,000
  $
  80,000
  Convertible
      note payable, annual interest rate of 12%, convertible into common stock at a variable rate per share and due June 2018
  —
  78,000
  Convertible note payable, annual interest rate of 8%, convertible into common stock at a variable rate per share and due November 2017
  65,000
  65,000
  Convertible note payable, annual interest rate of 8%, convertible into common stock at $0.11 per share and due August 2020
  50,000
  50,000
  Convertible note payable, annual interest rate of 5%, convertible into common stock at a variable rate per share and due September 2018
  82,500
  82,500
  Convertible note payable, annual interest rate of 8%, convertible into common stock at $0.30 per share and due October 13, 2020
  20,000
  —
  Unamortized debt discount
  (56,864
  )
  (91,480
  )
  Unamortized debt discount due to beneficial conversion feature
  (59,079
  )
  (-)
  106,557
  81,459
  Less current portion
  92,380
  58,432
  Convertible debt, net of current portion and debt discount
  $
  14,177
  $
  23,027
  During the year
  ended September 30, 2017, the Company entered into certain Note Purchase Agreements (collectively the "Purchase Agreements")
  in connection with the issuance of certain convertible promissory notes, in the aggregate principal amount of $685,000. The Purchase
  Notes are due in 36 months. The Purchase Notes bear interest at the rate of 8% compounded monthly. The Purchase Notes, together
  with all interest as accrued, are each convertible into shares of the Company's common stock at a conversion price of Eleven
  cents ($0.11) per share. Due to the beneficial conversion feature of these notes, the Company recorded $635,545 of debt discount
  as a contra liability and amortized $576,838 of the discount during the year ended September 30, 2017. During July 2017, certain
  note holders converted their respective principal and accrued interest into 5,720,066 shares of the Company's common stock.
  During October 2017, certain note holders converted their respective principal and accrued interest into 707,153 shares of the
  Company's common stock. As of December 31, 2017, the note balances and accrued interest are $5,000 and $419, respectively.
  On June 26, 2017,
  the Company entered into a Securities Purchase Agreement ("SAP") in connection with the issuance of a convertible promissory
  note (the "Power Up Note") in the aggregate principal amount of $78,000. The Power Up Note matures on June 30, 2018
  (the "Maturity Date"), and bears interest at the rate of 12% per annum. After 180 days, the Note may not be prepaid.
  Any amount of principal or interest on this note which is not paid when due shall bear interest at the rate of twenty two percent
  (22%) per annum from the due date. This note, together with all interest as accrued, is convertible into shares of the Company's
  common stock at a 35% discount to the lowest trading price in the 10-day period ending on the latest complete Trading Day prior
  to the Conversion Date. Due to the beneficial conversion feature of this note, the Company recorded $78,000 of debt discount as
  a contra liability and amortized $57,707 of the discount during the three months ended December 31, 2017. During the quarter ended
  December 2017, this note along with accrued interest and a prepayment were paid in full.
  On August 14, 2017,
  the Company entered into a Securities Purchase Agreement ("SAP") in connection with the issuance of a convertible promissory
  note (the "Kingdom Note") in the aggregate principal amount of $65,000. The Note matures on November 14, 2017 (the
  "Maturity Date"), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued,
  is convertible into shares of the Company's common stock at $0.11 per share. Due to the beneficial conversion feature of
  this note, the Company recorded $65,000 of debt discount as a contra liability and amortized $31,056 of the discount during the
  three months ended December 31, 2017. As of December 31, 2017, the note balance and accrued interest is $65,000 and $1,995, respectively.
  This note is in default and remains unpaid at December 31, 2017, however, the Company and the Payee entered into a Debt Conversion
  Agreement in February, 2018 pursuant to which the Payee received shares of the Company's Series A Convertible Preferred Stock
  in exchange for the full release of any and all obligations related to the Kingdom Note. Refer to NOTE 13. SUBSEQUENT EVENTS.
  13
  Table of Contents
  On August 23, 2017,
  the Company entered into a Securities Purchase Agreement ("SAP") in connection with the issuance of a convertible
  promissory note (the "Hayden Note") in the aggregate principal amount of $50,000. The Note matures on August 23, 2020
  (the "Maturity Date"), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued,
  is convertible into shares of the Company's common stock at $0.11 per share. Due to the beneficial conversion feature of
  this note, the Company recorded $50,000 of debt discount as a contra liability and amortized $4,197 of the discount during the
  three months ended December 31, 2017. As of December 31, 2017, the note balance and accrued interest is $50,000 and $1,434, respectively.
  This note remains unpaid at December 31, 2017.
  On September 12,
  2017, the Company entered into a Securities Purchase Agreement ("SAP") in connection with the issuance of a convertible
  promissory note (the "First Fire Note") in the aggregate principal amount of $82,500. The Note matures on September
  12, 2018 (the "Maturity Date"), and bears interest at the rate of 5% per annum. The Note, together with all interest
  as accrued, is convertible into shares of the Company's common stock at a 35% discount to the lowest trading price in the
  21-day period ending on the latest complete Trading Day prior to the Conversion Date. As of December 31, 2017, the note balance
  and accrued interest is $82,500 and $1,243. This note remains unpaid at December 31, 2017.
  On October 13, 2017,
  the Company entered into a Securities Purchase Agreement ("SAP") in connection with the issuance of a convertible promissory
  note (the "Escala Note") in the aggregate principal amount of $20,000. The Note matures on October 13, 2020 (the "Maturity
  Date"), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued, is convertible into
  shares of the Company's common stock at $0.30 per share. Due to the beneficial conversion feature of this note, the Company
  recorded $12,667 of debt discount as a contra liability and amortized $913 of the discount during the three months ended December
  31, 2017. As of December 31, 2017, the note balance and accrued interest is $20,000 and $346, respectively. This note remains unpaid
  at December 31, 2017.
  NOTE 8 – DERIVATIVE LIABILITY
  During June 2017,
  the Company entered into a Loan Agreement with an investor pursuant to which the Company issued a convertible promissory note in
  the principal amount of $78,000. The Note is convertible into shares of common stock at an initial conversion price subject to
  adjustment as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company's
  common stock at 65% of the trailing average highest closing bid price of the Company's common stock on the date of conversion.
  The Note accrues interest at a rate of 12% per annum and matures on June 30, 2018. The note was paid in full during the three months
  ended December 31, 2017.
  During September
  2017, the Company entered into a Loan Agreement with an investor pursuant to which the Company issued a convertible promissory
  note in the principal amount of $82,500. The Note is convertible into shares of common stock at an initial conversion price subject
  to adjustment as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company's
  common stock at 65% of the trailing average highest closing bid price of the Company's common stock on the date of conversion.
  The Note accrues interest at a rate of 5% per annum and matures on September 12, 2018.
  Due to the variable
  conversion price associated with these convertible promissory notes, the Company has determined that the conversion feature is
  considered a derivative liability. The accounting treatment of derivative financial instruments requires that the Company record
  the fair value of the derivatives as of the inception date of the Convertible Promissory Note and to adjust the fair value as of
  each subsequent balance sheet date.
  14
  Table of Contents
  The initial fair
  value of the embedded debt derivative of $238,785 was allocated as a debt discount in the amount of $147,500 and excess $91,285
  was charged to interest expenses, loss on derivative. The fair value of the described embedded derivative was determined using
  the Black-Scholes Model with the following assumptions:
  September 12, 2017
  June 26, 2017
  (1) dividend yield of
  0%;
  0%;
  (2) expected volatility of
  265%;
  250%,
  (3) risk-free interest rate of
  1.27%;
  1.20% - 1.24%,
  (4) expected life of
  1 year
  1 year
  (5) fair value of the Company's common stock of
  $0.54 per share.
  $0.67 per share.
  During the three
  months ended December 31, 2017 and 2016, the Company recorded the gain (loss) in fair value of derivative and derivative expense
  in the amount of $61,221 and $(14,319), respectively.
  For the three months
  ended December 31, 2017, $79,148 and $-0-, were expensed in the statement of operation as amortization of debt discount related
  to above notes and shown as interest expenses, respectively.
  The following table
  represents the Company's derivative liability activity for the period ended:
  Balance at September 30, 2017
  $
  231,733
  Change in fair value of derivative at period end
  (61,221
  )
  Derivative liability written off due to payment of related debt
  (67,953
  )
  Balance at December 31, 2017
  $
  102,559
  NOTE 9 – SHARE CAPITAL
  The Company is
  authorized to issue 475,000,000 shares of $.001 par value common stock and 25,000,000 shares of$.001 par value preferred stock.
  As of December
  31, 2017, the Company had 40,504,391 shares of its common stock issued and outstanding, with 117,500 shares of its Series A Convertible
  Preferred Stock issued and outstanding and -0- shares of its Series B Convertible Preferred Stock issued and outstanding..
  On December 29,
  2017, the Company issued 2,000,000 to Duplitrans and the legal counsel of Duplitrans in regards to the agreement with GandTex.
  On the date of the settlement, October 24, 2017, the shares had a fair market value of $640,000. Accordingly, the Company recorded
  $640,000 of stock based compensation during the three months ended December 31, 2017. All of the Company's 10,000,000 Series
  B Convertible Preferred Stock, previously issued to GandTex, were cancelled during the quarter ended December 31, 2017.
  Description of Preferred Stock:
  Series A Preferred
  Stock
  •
  As
                                           authorized in the Company's Amended and Restated Articles of Incorporation, the
                                           Company has 2,000,000 shares of Series A Preferred Stock ("Series A Stock")
                                           authorized with the following characteristics:
  •
  Holders
                                           of the Series A Stock shall be entitled to receive dividends or other distributions with
                                           the holders of the Common Stock on an "as converted" basis when, as, and
                                           if declared by the Directors of the
  Corporation.
  15
  Table of Contents
  •
  Holders
                                           of shares of Series A Stock, upon Board of Directors approval, may convert at any time
                                           following the issuance upon sixty-one (61) day written notice to the Corporation. Each
                                           share of Series A Preferred Stock shall be convertible into such number of fully paid
                                           and non-assessable shares of Common Stock as is determined by multiplying the number
                                           of issued and outstanding shares of the Corporation's Common Stock together with
                                           all other derivative securities, including securities convertible into or exchangeable
                                           for Common Stock, whether or not then convertible or exchangeable (b) subscriptions,
                                           rights, options and warrants to purchase shares of Common Stock, whether or not then
                                           exercisable, but entitled to vote on matters submitted to the Shareholders (collectively,
                                           "Derivative Securities"), issued by the Corporation and outstanding as of
                                           the Date of Conversion, by .000001, then multiplying that number of shares of Series
                                           A Stock to be converted.
  •
  In
                                           case of any consolidation or merger of the Corporation, the Corporation shall mail to
                                           each holder of Series A Stock at least thirty (30) days prior to
  the
                                           consummation of such event, a notice thereof and each such holder shall have the option
                                           to either (i) convert such holder's shares of Series A Stock into shares of Common
                                           Stock pursuant to this paragraph and thereafter receive the number of shares of Common
                                           Stock or other securities or property, or cash, as the case may be, to which a holder
                                           of the number of shares of Common Stock of the Corporation deliverable upon conversion
                                           of such Series A Stock would have been entitled upon conversion immediately preceding
                                           such consolidation, merger or conveyance, or (ii) exercise such holder's rights
                                           pursuant to Section 8.1(a) hereof; provided however that the Series A Stock shall not
                                           be subject to or affected as to the number of Conversion Shares or the redemption or
                                           liquidation price by reason of any reverse stock split affected prior or as a result
                                           of any reorganization.
  •
  In
                                           the event of a liquidation, the holders of shares of the Series A Stock shall be entitled
                                           to receive, prior to the holders of the other series of Preferred Stock and prior and
                                           in preference to any distribution of the assets or surplus funds of the Corporation to
                                           the holders of any other shares of stock of the Corporation by reason of their ownership
                                           of such stock, an amount equal to Five Dollar ($5.00) per share with respect to each
                                           share of Series B Stock owned as of the date of Liquidation, plus all declared but unpaid
                                           dividends with respect to such shares, and thereafter they shall share in the net Liquidation
                                           proceeds on an "as converted basis" on the same basis as the holders of the
                                           Common Stock.
  •
  The
                                           holders of each share of Series A Stock shall have that number of votes as determined
                                           by multiplying the number of issued and outstanding shares of the Corporation's
                                           Common Stock together with all other derivative securities issued by the Corporation
                                           and outstanding as of the Date of Conversion, whether or not then convertible or exchangeable,
                                           entitled to vote on matters submitted to the Shareholders, by .000001, then multiplying
                                           that number of shares of Series A Stock to be converted.
  •
  the
                                           Corporation shall have the option to redeem all of the outstanding shares of Series A
                                           Stock at any time on an "all or nothing" basis, unless otherwise mutually
                                           agreed in writing between the Corporation and the holders of shares of Series A Stock
                                           holding at least 51% of such Series A Stock, beginning ten (10) business days following
                                           notice by the Corporation, at a redemption price the higher of (a) Five Dollar ($5.00)
                                           per share, or (b) Fifty percent (50%) of the trailing average highest closing Bid price
                                           of the Corporation's Common Stock as published at www.OTCMarkets.com or the Corporation's
                                           primary listing exchange on the date of Notice of redemption, unless otherwise modified
                                           by mutual written consent between the Corporation and the Holders of the Series A Stock
                                           (the "Conversion Price"). Redemption payments shall only be made in cash within
                                           sixty (60) days of notice by the Corporation to redeem.
  •
  The
                                           shares of Series A Stock acquired by the Corporation by reason of conversion or otherwise
                                           can be reissued, but only as an amended class, not as shares of Series A Stock.
  16
  Table of Contents
  Series
  B Preferred Stock
  •
  In
                                           conjunction with the unwinding of the Asset Acquisition with GandTex, the Company cancelled
                                           all 10,000,000 shares of its Series B Preferred Stock ("Series B Stock").
                                           Pursuant to the terms of the Series B Stock, the shares of Series B Stock acquired by
                                           the Corporation by reason of conversion or otherwise, can be reissued but only as an
                                           amended class, not as shares of Series B Stock.
  Therefore, the Company returned
  the Series B Stock to its authorized but unissued Preferred Stock and no longer has a class of Series B Convertible Preferred Stock.
  Stock Options
  On November 15,
  2016, the Board approved the grant of 1,500,000 common stock purchase options to Fred Luke, the Company's President, at an
  exercise price of not less than One Hundred Ten percent (110%) of the ten (10) day lowest trailing average closing bid price of
  such shares on the date of execution of the Option Agreement which was Fourteen cents ($0.14) per share and subject to certain
  adjustments on November 15, 2016. The options vested immediately.
  On January 31,
  2017, the Board approved the grant of 120,000 common stock purchase options Dr. Youxue Wang, the Director of Research for NuLife
  BioMed. The option vested immediately. The exercise price of the options was calculated at January 31, 2017 at One Hundred Ten
  percent (110%) of the 10-day trailing average closing Bid price of such shares, which was Seventy cents ($0.70) per share.
  On May 15, 2017,
  the Board approved the grant of 1,500,000 common stock purchase options to John Hollister, the Company's former CEO, at an
  exercise price of not less than One Hundred Ten percent (110%) of the ten (10) day lowest trailing average closing bid price of
  such shares on a certain date of agreement which was Fourteen cents ($0.12) per share and subject to certain adjustments on October
  17, 2016. The options vested based on certain goals and as such 500,000 common stock options were earned prior to Mr. Hollister's
  employment ending with the Company, the remaining 1,000,000 common stock options expired due to his resignation.
  Stock option transactions for the
  three months ended December 31, 2017 are summarized as follows:
  Shares
  Weighted
  Average
  Exercise
  Price
  Weighted
  Average
  Remaining
  Term
  Aggregate
  Intrinsic Value
  Outstanding, September 30, 2017
  3,120,000
  $
  0.17
  2.26
  $
  355,200
  Granted
  -
  -
  -
  $
  -
  Exercised
  -
  -
  Expired
  (1,000,000)
  0.12
  2.08
  $
  120,000
  Outstanding, December 31, 2017
  2,120,000
  $
  0.17
  2.00
  $
  355,200
  Exercisable, December 31, 2017
  2,120,000
  $
  0.17
  2.00
  $
  355,200
  The initial fair
  value of the options was $308,909 charged to operating expense during the year ended September 30, 2017. The fair value of the
  option was determined using the Black-Scholes Model with the following assumptions:
  (1) dividend yield of
  0%;
  (2) expected volatility of
  236%,313%,223%
  (3) risk-free interest rate of
  1.28%,1.46%,.98%
  (4) expected life of
  3 years, and
  (5) fair value of the Company's common stock of
  $0.13, $0.60, $0.11 per share.
  17
  Table of Contents
  Warrants
  On June 10, 2016,
  the Board approved the grant of 250,000 common stock purchase warrants to a consultant at an exercise price of not less than One
  Hundred Ten percent (110%) of the ten (10) day lowest trailing average closing bid price of such shares on the date of execution
  of the warrant which was $0.66 per share. The warrants vested immediately.
  Warrant transactions for the three
  ended December 31, 2017 are summarized as follows:
  Shares
  Weighted Average
  Exercise
  Price
  Weighted Average Remaining
  Term
  Aggregate
  Intrinsic Value
  Outstanding, September 30, 2017
  250,000
  $
  0.66
  2.70
  Granted
  -
  -
  -
  Exercised
  -
  -
  Expired
  -
  -
  Outstanding, December 31, 2017
  250,000
  $
  0.66
  2.44
  Exercisable, December 31, 2017
  250,000
  $
  0.66
  2.44
  The initial fair
  value of the options was $144,800 charged to operating expense during the year ended September 30, 2017. The fair value of the
  option was determined using the Black-Scholes Model with the following assumptions:
  (1) dividend yield of
  0%;
  (2) expected volatility of
  249%
  (3) risk-free interest rate of
  1.5%
  (4) expected life of
  3 years, and
  (5) fair value of the Company's common stock of
  $0.60 per share.
  The
  Company recorded $-0- and $186,904 of stock compensation expense in the statements of operations for the three months ended December
  31, 2017 and 2016, respectively, related to non-vested share-based compensation arrangements granted under existing stock option
  plans.
  As
  of December 31, 2017, there was $0 of total unrecognized compensation cost related to non-vested share-based compensation arrangements
  granted under existing stock option plans.
  NOTE 10 -
  CONTINGENCY
  As of December 31,
  2017, as described in Note 6, the Company has accrued $53,200 in accrued expenses, note payable of $74,500 and accrued
  interest of $14,366 due EWSD. At September 30, 2017 the Company owed EWSD the aggregated amount of $138,311, which is past due
  and has been in default since October 31, 2016. On top of the amount accrued by the Company, Mr. Loiselle had demanded for a penalty
  fee of $101,235, which is approximately 18% monthly default rate on the amount past due. We believe the penalty fee imposed is
  invalid and are currently in dispute with Mr. Loiselle. See NOTE 6. above.
  NOTE 11
  – FORGIVENESS OF ACCOUNTS PAYABLE
  On November 15,
  2017, a service vendor with a balance due of $73,644 agreed to cancel the debt owed by The Company. Accordingly, the Company recorded
  $73,644 of forgiveness of debt during the three months ended December 31, 2017.
  18
  Table of Contents
  NOTE 12 -
  LEASE AGREEMENT
  During May 2017,
  the executed a 5-year lease for a laboratory at NOVA Southeastern University at which the Company will be utilizing the NuLife
  Technique to process organs, as well as conducting bench research to better characterize and assess the impact of the technique.
  The lease calls for monthly payments of $2,582, which includes the initial base rent of $1,925 along with applicable taxes and
  shared operating expenses. The lease required a security deposit in the amount of $4,871 and requires a 4% increase in base rent
  annually. Rent expense for three months ended December 31, 2017 and 2016 was $8,225 and $-0-, respectively.
  Future minimum lease
  payments are as follows for the years ending:
  September 30, 2018 (remaining months)
  $
  17,633
  September 30, 2019
  24,344
  September 30, 2020
  25,318
  September 30, 2021
  26,331
  September 30, 2022
  18,016
  $
  111,642
  NOTE 13 -
  SUBSEQUENT EVENTS
  On
  January 30, 2018, the Master Service Agreement as described in note 5 entered into on June 10, 2017 was terminated and the Company
  received a refund of $38,000 in cash.
  19
  Table of Contents
  Effective
  February 20, 2018 the Company entered into two Debt Conversions Agreements, one with Kingdom Building Inc.
  ("Kingdom") and MZHCI LLC ("MZ") pursuant to which Kingdom and MZ agreed to exchange an aggregate of
  approximately $445,296 of combined Notes Payable and Accounts Payable into 694,041 and 1,086,176 shares, respectively, of the
  Company's Series A Convertible Preferred Stock.
  ITEM 2. MANAGEMENT'S DISCUSSION AND
  ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
  The information contained in this
  Form 10-Q is intended to update the information contained in our Annual Report on Form 10-K for the year ended September 30, 2017
  and presumes that readers have access to, and will have read, the "Management's Discussion and Analysis of Financial Condition
  and Results of Operations" and other information contained in such Form 10-K. The following discussion and analysis also should
  be read together with our financial statements and the notes to the financial statements included elsewhere in this Form 10-Q.
  Except for historical information,
  the matters discussed in this section are forward looking statements that involve risks and uncertainties and are based upon judgments
  concerning various factors that are beyond the Company's control. Consequently, and because forward-looking statements are inherently
  subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed
  in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report.
  We strongly encourage investors to carefully read the factors described elsewhere in this report in the section entitled "Risk
  Factors" for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking
  statements. We assume no responsibility to update the forward-looking statements contained in this quarterly report on Form 10-Q.
  The following should also be read in conjunction with the unaudited Financial Statements and notes thereto that appear elsewhere
  in this report.
  Company Overview
  As
  a result of the Company not receiving the working capital promised by certain third parties, development of the two business segments
  described below has been slow, and generated no revenues since its inception on October 15, 2013. In August 2017, changing our
  name and pursuing the various biomedical opportunities which had been presented to us, one of which, the patents and other rights
  owned by GandTex seemed very attractive and we elected to acquire the patents purportedly owned by GandTex and develop what is
  now termed the "NuLife Process" or NuLife Technique". As a result of operating difficulties relating primarily
  to the hurricanes and related severe weather in southern Florida, the home of our Animal Trials, and the discovery that certain
  critical information related to the actual surgical process has been withheld by the inventor of the NuLife Process, we suspended
  the organ transplantation activities in October 2017. In connection with the return of the Exclusive License to Duplitrans and
  the return of and the patent rights acquired from GandTex pursuant to individual Settlement and Release Agreements with Duplitrans
  and GandTex (the "Settlement Agreements).
  While
  the organ transplantation activities were suspended we began investigating other applications of the NuLife Process, in particular
  the Wound Care Technique.
  To date, the Company's participation in the proposed Wound Care activities are still in
  the investigation stage, without significant expenditures by the Company due to our efforts to maintain adequate funding for our
  corporate operations. Further, the commercial relationship between the NuGenesis and Duplitrans has not yet been established in
  an adequate definitive joint venture agreement, but only through the MOU during this exploratory stage of the business. Neither
  the Company or NuGenesis currently have the necessary funding to resume the development of the Wound Care Technique, and the reduction
  of the MOU to a definitive agreement is contingent upon either the Company or NuGenesis obtaining the funding necessary to carry
  the proposed development through to completion
  Online marketplace
  and community
  The Company's initially-defined
  business strategy is to acquire and/or develop and market software and services that will significantly enhance the performance
  and functionality of the Internet services used by individuals and by small to medium sized businesses. However, .it appears that
  the Website will not be competitive in the "service" sector of the Internet space without certain modifications, ,
  but could have other applications which we may consider pursuing depending upon the results of the current Animal Trials, our investigation
  of the Wound Care Process and the potential opportunities in the oncology data management space. Since the acquisition of the organ
  transplant technology, we narrowed the focus of our platform to the healthcare industry and have, for now, suspended the modification
  of the Website.
  20
  Table of Contents
  However,
  with the
  Settlement Agreements
  and unwinding of the Asset Acquisition, and the shift
  in our structure and direction in the healthcare industry to attempt to become involved with NuGenesis in the development of the
  Wound Care Technique, as funding becomes available we intend to either (a) pursue the joint venture envisioned by the MOU with
  NuGenesis in the development of the Wound Care Technique, or (b) refocus on our Website and (i) modifying our online marketplace
  and community to focus on healthcare professionals and those in need of individual at-home and post-operative care, together with
  Hospitals and physicians who need part time or additional personnel due for expansion, or (ii) simply updating the Website as www.anytimeJobs.com.
  Critical Accounting Policies
  The preparation
  of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States
  of America requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses
  and related disclosures of contingent assets and liabilities in the financial statements and accompanying notes. The SEC has defined
  a company's critical accounting policies as the ones that are most important to the portrayal of the company's financial condition
  and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result
  of the need to make estimates of matters that are inherently uncertain. We believe that our estimates and assumptions are reasonable
  under the circumstances; however, actual results may vary from these estimates and assumptions. We have identified in Note 2 -
  "Summary of Accounting Policies" to the Financial Statements contained in this Quarterly Report certain critical accounting
  policies that affect the more significant judgments and estimates used in the preparation of the financial statements
  .
  Going Concern
  Our auditor has
  issued a "going concern" qualification as part of its opinion in the Audit Report for the fiscal year ended September
  30, 2017, and our financial statements as of and for the year then ended include a "going concern" footnote (See Footnote
  3 – Going Concern) disclosing that our ability to continue as a going concern is contingent on us to be able to raise working
  capital to generate revenue by completing and launching our online marketplace and community portal and implementing the new business
  strategy of developing the NuLife Process.
  Results of Operation
  Three Months Ended December 31,
  2017 and 2016
  Revenue.
  Revenue was $0
  for the three months ended December 31, 2017 and 2016.
  Cost of Sales.
  Cost of sales
  was $0 for the three months ended December 31, 2017 and 2016.
  Operating Expenses.
  Operating expenses
  were $811,769 and $402,260 for the three months ended December 31, 2017 and 2016, respectively. Operating expenses consist of general
  and administrative expenses and related party compensation. During the three months ended December 31, 2017 and 2016 general and
  administrative expenses were $768,775 and $98,856, respectively. During the three months ended December 31, 2017 and 2016, the
  Company recorded $640,000 and $-0- of stock-based compensation to non-related parties. During the three months ended December 31,
  2017 and 2016 related party compensation was $42,994 and $303,404, respectively. Related party compensation included $186,904 of
  stock-based compensation during the three months ended December 31, 2016.
  21
  Table of Contents
  Interest Expense.
  Interest expense
  was $201,254 and $36,479 for the three months ended December 31, 2017 and 2016, respectively, which related to interest accrued
  on borrowings, which were greater at December 31, 2017 as a result of newly issued debt. Included in interest expense for the three
  months ended December 31, 2017 and 2016, was also $91,617 and $14,392, respectively, of non-cash interest expense related to the
  amortization of the debt discount and beneficial conversion feature.
  Interest Income.
  Interest income
  was $-0- and $504 for the three months ended December 31, 2017 and 2016, respectively, which related to interest due on notes receivable
  and interest earned in bank accounts, which were greater in the three months ended December 31, 2017.
  Forgiveness of Accounts Payable.
  During the three
  months ended December 31, 2017, a vendor cancelled the amount the Company owed. Accordingly, the Company recorded a forgiveness
  of debt in the amount of $73,644.
  Gain(Loss) on derivative.
  The Company recorded
  a net gain on derivative in the amount of $61,221 in the three months ended December 31, 2017 compared to a loss on derivative
  of $14,319 during the three months ended December 31, 2016.
  Liquidity and Capital Resources
  The following
  is a summary of the Company's cash flows provided by (used in) operating, investing, and financing activities for the three months
  ended December 31, 2017 and 2016:
  2017
  2016
  Operating Activities
  $
  (92,493
  )
  $
  (182,568
  )
  Investing Activities
  -
  -
  Financing Activities
  48,410
  685,000
  Net Effect on Cash
  $
  (44,083)
  $
  502,432
  Since acquiring
  the business plan and Website, during our fiscal year ended September 30, 2016, most of our resources and work was devoted to the
  development of the Website segment of our business. However, this has been suspended for the time being due to certain modifications
  needed to eliminate the risk of cyber-attacks. When those procedures are completed, which we believe will occur over several months
  following the receipt of adequate financing, we may resume work on our Website as well further internal development of software
  for which we have developed our initial framework of and completed some coding. We believe that the work needed to initiate and
  complete the software development for our online marketplace and community portal, attract developers, and initiate our marketing
  plans, including the development of a saleable product suite, may be in excess of $100,000 if outside contractors and experts are
  used. If we are able to secure funding to outsource these procedures, of which there are no assurances, we will then commence the
  launch of our intended services and software products to the public. If we are able to use internal resources only (primarily consisting
  of the services of our president and chief financial officer), the process will take much longer and our initial launch may be
  limited to a much smaller target market. If we are unable to raise any funds from third party sources, the development costs would
  have to be funded by current shareholders, management or by third-parties through the issuance of Convertible or Demand Promissory
  Notes. While we have previously engaged the services of an established software development firm which we used on an as "needed
  basis", their involvement is limited by our ability to raise financing. Our goal would be to have software products available,
  services available, multiple sales channels and a comprehensive corporate website up and running within one year after receipt
  of adequate financing, but there is no way of estimating what the likelihood of achieving that goal would be.
  22
  Table of Contents
  If a market for
  our shares ever develops, of which there can be no assurances, we may continue to use restricted shares of our common stock or
  stock options to compensate employees/consultants and independent contractors wherever possible. We cannot predict the likelihood
  or source of raising capital or funds that may be needed to complete the development of our business plan and its stages as outlined
  above.
  As a public company,
  we will incur ongoing expenses associated with professional fees for accounting, legal and a host of other expenses including annual
  reports and proxy statements, if required. We estimate that these costs will range up to $50,000 per year over the next few years
  and may be significantly higher if our business volume and transactional activity increases, and we would not be subject to the
  requirements of Section 404 of the Sarbanes-Oxley Act of 2002 for an opinion on our system on internal controls by our independent
  audit firm unless and until we exceed $75 million in market capitalization. These obligations may reduce our ability and resources
  to expand our business plan and activities. We hope to be able to use our status as a public company to increase our ability to
  use noncash means of settling outstanding obligations (i.e. issuance of restricted shares of our common stock) and compensate independent
  contractors who provide professional services to us, although there can be no assurances that we will be successful in any of these
  efforts. We will also reduce compensation levels paid to management (if we attract or retain outside personnel to perform this
  function) if there is insufficient cash generated from operations to satisfy these costs.
  We are presently
  seeking equity and debt financing for both segments of our business. However, these actions, if successful, could result in dilution
  of the ownership interests of existing shareholders and further dilute common stock book value, and such dilution may be material.
  The Company may offer shares of its common stock to settle a portion of the professional fees incurred in connection with its registration
  statement. No negotiations have taken place with any professional and no assurances can be made as to the likelihood that any professional
  will accept shares in settlement of obligations due them.
  As of December
  31, 2017, we owed $610,410 in accounts payable, accrued expenses and to related parties, a substantial portion of which are past
  due. The only agreements, written or oral, with any vendors or other providers for payment of services or expenses are with respect
  to (i) contracted investor relation services, and (ii) compensation to the Company's President, our Chief Executive Officer and
  our Chief Financial Officer, one of whom is a director. There are no other significant liabilities at December 31, 2017.
  As of December
  31, 2017, the Company had one note payable issued and outstanding to a third-party lender with a total principle of $25,000 and
  accrued interest of $15,912. The note was due on June 30, 2015, has an interest rate of 12%. This note is in default and remains
  unpaid at December 31, 2017.
  As of December 31,
  2017, the Company had three notes payable issued and outstanding with a former director with a total principle of $74,500 and accrued
  interest of $14,366. The three notes, in the amount of $47,000, $15,000 and $12,500, were issued on January 14, 2016. February
  10, 2016 and February 29, 2016, respectively. The three notes are due on the earlier of one week after the closing of a certain
  contemplated farm property acquisition or July 31, 2016, and have an interest rate of 10%. The former director for all three notes
  is East West Secured Developments, LLC, an Arizona Limited Liability Company ("EWSD") of which Mr. Brian Loiselle,
  the EWSD Managing Member, was also a former director of the Company. On June 30, 2016, the Company entered into Amendment #1 to
  these three notes to extend the due date to one week after the closing of a certain contemplated farm property acquisition or October
  31, 2016. The three notes have been reclassified to non-related party debt. See NOTE 6 above.
  On December 28,
  2017, the Company entered into a note payable in the aggregate principal amount of $106,410. The Note matures on March 31, 2018,
  and bears interest at the rate of 12% per annum. As of December 31, 2017, the note balance and accrued interest is $106,410 and
  $105, respectively. This note remains unpaid at December 31, 2017
  As of December
  31, 2017, the Company had five convertible notes payable issued and outstanding with a total principle of $222,500 and accrued
  interest of $5,437. The notes are due December 31, 2017 through October 13, 2020 and have interest rates of 5% to 12%. The notes
  remain unpaid as of December 31, 2017.
  Off-Balance Sheet Arrangements
  We have not entered
  into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
  condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
  resources and would be considered material to investors.
  23
  Table of Contents
  Contractual Obligations
  As a "smaller reporting company"
  as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.
  Item 3. Quantitative and Qualitative
  Disclosures about Market Risks
  Not applicable because we are a smaller
  reporting company.
  Item 4. Controls and Procedures
  Evaluation of Disclosure Controls
  and Procedures
  Pursuant to Rule 13a-15(b) under the
  Securities Exchange Act of 1934 ("Exchange Act"), the Company carried out an evaluation, with the participation of
  the Company's management, including the Company's President (the "President") and principal Financial Officer,
  of the effectiveness of the Company's disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange
  Act) as of the end of the period covered by this report. Based upon that evaluation, the Company's President and principal
  financial officer concluded that the Company's disclosure controls and procedures were not effective to ensure that information
  required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed,
  summarized and reported, within the time periods specified in the SEC's rules and forms, and that such information is accumulated
  and communicated to the Company's management, including the Company's President and principal financial officer, as
  appropriate, to allow timely decisions regarding required disclosure as a result of continuing material weaknesses (such as the
  absence of an audit committee and absence of qualified independent directors) in its internal control over financial reporting.
  Changes in Internal Controls Over
  Financial Reporting
  There have been no changes in the Company's
  internal control over financial reporting during the latest fiscal quarter that have materially affected, or are reasonably likely
  to materially affect, the Company's internal control over financial reporting.
  24
  Table of Contents
  PART II - OTHER INFORMATION
  Item 1. Legal Proceedings.
  The Company owes
  on promissory notes that have an aggregate principal amount of $74,500 and are simple promissory notes with 10% annual interest
  to EWSD. The notes are in default, but there is not a default interest provided in the notes. Therefore, the notes continue to
  accrue interest at 10% per annum until paid or collected. Mr. Loiselle is demanding 18% per month interest for the past four months
  to the present. The Company has disputed this interest that is not detailed on the notes. Furthermore, Mr. Loiselle is claiming
  unpaid compensation of $10,000 per month for services without an agreement with the Company. These charges are also being disputed
  by the Company. These disputes represent a material risk, and may be litigated in the future other than the aforementioned, the
  Company currently has no other litigation pending, threatened or contemplated, or unsatisfied judgments.
  From time to time,
  we are also a party to certain legal proceedings incidental to the normal course of our business including the enforcement of our
  rights under contracts with contractors and suppliers. While the outcome of these legal proceedings cannot at this time be predicted
  with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of
  operations.
  Item 1A. Risk Factors
  Not applicable because
  we are a smaller reporting company.
  Item 2. Unregistered Sales of Equity
  Securities and Use of Proceeds
  In October 2013,
  following the Company's incorporation on October 15, 2013, the Company issued 7,250,00 shares of our common, now 21,750,000 shares
  following the 3:1 forward stock split, stock to its founder, Derek Cahill, as consideration for the purchase of a business plan
  along with a website. The acquisition of the business plan and website was valued at $72,500.
  On October 29, 2013,
  the Company completed a private placement whereby it issued 5,400,000 shares of common stock to accredited investors at $0.003
  per share for total gross proceeds of $18,000.
  On April 16, 2014,
  the Company completed a public offering whereby it issued 1,735,800 shares of common stock at $0.042 per share for total gross
  proceeds of $72,325. The Company's Registration Statement on Form S-1 was declared effective March 6, 2014.
  On August 7, 2015,
  the Company granted 100,000 shares of restricted common stock to its chief operating officer. On the date of the grant, the shares
  were valued at $.61 per share which was the unadjusted closing share price on that date for a fair value of $61,000. The shares
  vest over a six-month period, with the vested shares recorded on the accompanying balance sheet under equity - shares to be issued.
  The subject 100,000 shares of common stock will be issued in a subsequent period.
  The Company amended
  and restated that certain outstanding promissory note of the Company, dated July 3, 2015, and in the principal amount of $50,025
  (the "Default Note"). The replacement convertible promissory note (the "Exchange Note") matures on December
  31, 2017 (the "Maturity Date"), and bears interest at the rate of 8% per annum, and the principal and interest due
  thereunder may be prepaid at any time. The Exchange Note, together with all interest as accrued, is convertible into shares of
  the Company's common stock at $0.11, which amount represents the average trailing average high closing Ask price of the Company's
  common stock as of the date of issuance of the Exchange Note.
  On September 2,
  2016, the Company entered into those certain Note Purchase Agreements (collectively, the "Purchase Agreements") in
  connection with the issuance of certain convertible promissory notes (collectively, the "Purchase Notes") in the aggregate
  principal amount of $50,000. All of the Purchase Notes mature thirty-six months from the date of issuance (the "Maturity
  Date"), and bear interest at the rate of 10% per annum. Each of the Purchase Notes may be prepaid until the Maturity Date
  at 110% of the principal and interest amount outstanding. The Purchase Notes, together with all interest as accrued, are each convertible
  into shares of the Company's common stock at 50% of the trailing average highest closing bid price of the Company's
  common stock on the date of conversion. The Purchase Agreements and the Purchase Notes contain representations, warranties, conditions,
  restrictions, and covenants of the Company that are customary in such transactions with smaller companies.
  25
  Table of Contents
  Also, on September
  2, 2016, the Company amended and restated the Default Note. The Exchange Note matures on December 31, 2017, and bears interest
  at the rate of 8% per annum, and the principal and interest due thereunder may be prepaid at any time. The Exchange Note, together
  with all interest as accrued, is convertible into shares of the Company's common stock at $0.11, which amount represents
  the average trailing average high closing Ask price of the Company's common stock as of the date of issuance of the Exchange
  Note.
  The Purchase Notes
  may be accelerated by the holders thereof in the event of default. In addition, the amounts due and payable under the Purchase
  Notes (and, consequently, the number of shares of common stock convertible thereunto) may be increased to 150% of the principal
  and interest amounts of the Purchase Notes. The Purchase Notes are a direct financial obligation of the Company and are considered
  a current liability of the Company for accounting purposes.
  We relied upon Section
  4(2) of the Securities Act of 1933, as amended for the above private placement issuances. We believed that Section 4(2) was available
  because:
  •	None of
  these issuances involved underwriters, underwriting discounts or commissions
  •	We placed
  restrictive legends on all certificates issued
  •	No sales
  were made by general solicitation or advertising
  •	Sales were
  made only to accredited investors
  In connection with
  the above transactions, we provided the following to all investors:
  •	Access to
  all our books and records
  •	Access to
  all material contracts and documents relating to our operation
  •	The opportunity
  to obtain any additional information, to the extent we possessed such information, necessary to verify the accuracy of the information
  to which the investors were given access.
  Pursuant
  to the terms of the Asset Purchase Agreement with GandTex, on December 30, 2016 the Board approved the issuance of 10,000,000 shares
  of the Company's Series B Convertible Preferred Stock to GandTex. The shares were released to GandTex concurrent with the
  closing on January 29, 2017.
  On
  January 20 , 2017, the Company entered into a Debt Conversion Agreement (the "Conversion Agreement") in respect of
  $13,750 of the accruing monthly fees due to MZHCI, LLC("MZ") by the Company pursuant to the Investor Relations Consulting
  Agreement between MZ and the Company dated April 1, 2015 (the "Debt") together with a release by MZ in favor of the
  Company for any claims for reimbursement of any and all due diligence expenses, investigative costs or any other type of fees or
  costs incurred by MZ related to the recent purchase by the Company of the GandTex Assets. Pursuant to the terms of the Conversion
  Agreement, the Company issued to MZ an aggregate of 55,000 shares of restricted Series A Convertible Preferred Stock.
  On
  February 28, 2017 the Company entered into an Advisory Agreement with Global Business Strategies Inc.("Global"), a
  Company owned by the Company's President Fred G. Luke ("the "Global Agreement"), pursuant to which the
  Company retained Global to provide management advice and corporate development strategies, and to make Mr. Luke available to serve
  as the Company's President, for an aggregate of $8,500 per month and, subject to the condition that Global effected filing
  of the Company's its Quarterly Report for the period ending December 31, 2016 on Form 10-Q on a timely basis, Global received
  an aggregate of 55,000 shares of restricted Series A Convertible Preferred Stock.
  On
  June 26, 2017, the Company entered into a Securities Purchase Agreement ("June SPA") in connection with the issuance
  of a convertible promissory note ("June Note") in the aggregate principal amount of $78,000. The June Note matures
  on June 30, 2018 (the "Maturity Date"), and bears interest at the rate of 12% per annum. After 180 days, the June Note
  may not be prepaid. Any amount of principal or interest on the June Note which is not paid when due shall bear interest at the
  rate of twenty two percent (22%) per annum from the due date. The June Note, together with all interest as accrued, is convertible
  into shares of the Company's common stock at a 35% discount to
  26
  Table of Contents
  the lowest
  trading price in the 10-day period ending on the latest complete Trading Day prior to the Conversion Date. The June SPA and the
  June Note contain representations, warranties, conditions, restrictions, and covenants of the Company that are customary in such
  transactions with smaller companies.
  On August 14, 2017,
  the Company entered into a Securities Purchase Agreement ("SAP") in connection with the issuance of a convertible promissory
  note (the "Kingdom Note") in the aggregate principal amount of $65,000. The Note matures on November 14, 2017 (the
  "Maturity Date"), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued,
  is convertible into shares of the Company's common stock at $0.11 per share. Due to the beneficial conversion feature of
  this note, the Company recorded $65,000 of debt discount as a contra liability and amortized $31,056 of the discount during the
  three months ended December 31, 2017. As of December 31, 2017, the note balance and accrued interest is $65,000 and $1,995, respectively.
  This note is in default and remains unpaid at December 31, 2017, however, the Company and the Payee entered into a Debt Conversion
  Agreement in February, 2018 pursuant to which the Payee received shares of the Company's Series A Convertible Preferred Stock
  in exchange for the full release of any and all obligations related to the Kingdom Note. Refer to NOTE 13. SUBSEQUENT EVENTS.
  On August 23, 2017,
  the Company entered into a Securities Purchase Agreement ("SAP") in connection with the issuance of a convertible promissory
  note (the "Hayden Note") in the aggregate principal amount of $50,000. The Note matures on August 23, 2020 (the "Maturity
  Date"), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued, is convertible into
  shares of the Company's common stock at $0.11 per share. Due to the beneficial conversion feature of this note, the Company
  recorded $50,000 of debt discount as a contra liability and amortized $4,197 of the discount during the three months ended December
  31, 2017. As of December 31, 2017, the note balance and accrued interest is $50,000 and $1,424, respectively. This note remains
  unpaid at December 31, 2017.
  On September 12,
  2017, the Company entered into a Securities Purchase Agreement ("SAP") in connection with the issuance of a convertible
  promissory note (the "First Fire Note") in the aggregate principal amount of $82,500. The Note matures on September
  12, 2018 (the "Maturity Date"), and bears interest at the rate of 5% per annum. The Note, together with all interest
  as accrued, is convertible into shares of the Company's common stock at a 35% discount to the lowest trading price in the
  21-day period ending on the latest complete Trading Day prior to the Conversion Date. As of December 31, 2017, the note balance
  and accrued interest is $82,500 and $1,243. This note remains unpaid at December 31, 2017.
  On October 13, 2017,
  the Company entered into a Securities Purchase Agreement ("SAP") in connection with the issuance of a convertible promissory
  note (the "Escala Note") in the aggregate principal amount of $20,000. The Note matures on October 13, 2020 (the "Maturity
  Date"), and bears interest at the rate of 8% per annum. The Note, together with all interest as accrued, is convertible into
  shares of the Company's common stock at $0.30 per share. Due to the beneficial conversion feature of this note, the Company
  recorded $12,667 of debt discount as a contra liability and amortized $913 of the discount during the three months ended December
  31, 2017. As of December 31, 2017, the note balance and accrued interest is $20,000 and $346, respectively. This note remains unpaid
  at December 31, 2017.
  On December 28,
  2017, the Company entered into a note payable in the aggregate principal amount of $106,410. The Note matures on March 31, 2018,
  and bears interest at the rate of 12% per annum. As of December 31, 2017, the note balance and accrued interest is $106,410 and
  $105, respectively. This note remains unpaid at December 31, 2017
  On December 29,
  2017, the Company issued 2,000,000 to Duplitrans and the legal counsel of Duplitrans in regards to the agreement with GandTex.
  On the date of the settlement, October 24, 2017, the shares had a fair market value of $640,000. Accordingly, the Company recorded
  $640,000 of stock based compensation during the three months ended December 31, 2017. All of the Company's 10,000,000 Series
  B Convertible Preferred Stock, previously issued to GandTex, were cancelled during the quarter ended December 31, 2017.
  As of December
  31, 2017, the Company had five convertible notes payable issued and outstanding with a total principle of $222,500 and accrued
  interest of $5,437. The notes are due December 31, 2017 through October 13, 2020 and have interest rates of 5% to 12%. The notes
  remain unpaid as of December 31, 2017.
  27
  Table of Contents
  Item 3. Defaults Upon Senior Securities.
  None
  Item 4. Mine Safety Disclosures
  Not Applicable.
  Item 5. Other Information.
  None.
  28
  Table of Contents
  Item 6. Exhibits.
  Exhibit No.
  Description
  3.1
  3.2
  31.1
  C
  ertification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  .
  31.2
  Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  .
  32.1
  Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  .
  32.2
  Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  .
  101.INS
  XBRL Instance Document
  101.SCH
  XBRL Taxonomy Extension Schema Document
  101.CAL
  XBRL Taxonomy Extension Calculation Linkbase Document
  101.DEF
  XBRL Taxonomy Extension Definition Linkbase Document
  101.LAB
  XBRL Taxonomy Extension Label Linkbase Document
  101.PRE
  XBRL Taxonomy Extension Presentation Linkbase Document
  SIGNATURES
  Pursuant to the requirements of the
  Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
  duly authorized.
  NuLife Sciences, Inc.
  Date:
      February 23, 2018
  By:
  /s/  Fred Luke
  Fred Luke
  President
  (Duly Authorized Officer and Principal Executive Officer)
  29